false00018165813/31/20222022FYDecember
31http://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMember0.500018165812022-01-012022-03-310001816581us-gaap:CommonStockMember2022-01-012022-03-310001816581us-gaap:WarrantMember2022-01-012022-03-3100018165812022-05-05xbrli:shares00018165812022-03-31iso4217:USD00018165812021-12-310001816581srt:AffiliatedEntityMember2022-03-310001816581srt:AffiliatedEntityMember2021-12-31iso4217:USDxbrli:shares00018165812021-01-012021-03-310001816581us-gaap:RedeemableConvertiblePreferredStockMember2021-12-310001816581us-gaap:CommonStockMember2021-12-310001816581us-gaap:AdditionalPaidInCapitalMember2021-12-310001816581us-gaap:RetainedEarningsMember2021-12-310001816581us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001816581us-gaap:CommonStockMember2022-01-012022-03-310001816581us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001816581us-gaap:RetainedEarningsMember2022-01-012022-03-310001816581us-gaap:RedeemableConvertiblePreferredStockMember2022-03-310001816581us-gaap:CommonStockMember2022-03-310001816581us-gaap:AdditionalPaidInCapitalMember2022-03-310001816581us-gaap:RetainedEarningsMember2022-03-310001816581us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001816581us-gaap:RedeemableConvertiblePreferredStockMember2020-12-310001816581us-gaap:CommonStockMember2020-12-310001816581us-gaap:AdditionalPaidInCapitalMember2020-12-310001816581us-gaap:RetainedEarningsMember2020-12-310001816581us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100018165812020-12-310001816581us-gaap:CommonStockMember2021-01-012021-03-310001816581us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001816581us-gaap:RedeemableConvertiblePreferredStockMember2021-01-012021-03-310001816581us-gaap:RetainedEarningsMember2021-01-012021-03-310001816581us-gaap:RedeemableConvertiblePreferredStockMember2021-03-310001816581us-gaap:CommonStockMember2021-03-310001816581us-gaap:AdditionalPaidInCapitalMember2021-03-310001816581us-gaap:RetainedEarningsMember2021-03-310001816581us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100018165812021-03-31xbrli:pure0001816581oust:ColonnadeAcquisitionCorpMemberus-gaap:CommonClassBMember2020-12-210001816581oust:ColonnadeAcquisitionCorpMemberoust:ConversionOfClassBCommonStockToClassACommonStockMember2020-12-210001816581oust:ColonnadeAcquisitionCorpMemberus-gaap:CommonClassAMember2020-12-210001816581oust:ColonnadeAcquisitionCorpMemberoust:ConversionOfClassACommonStockToCommonStockMember2020-12-2100018165812020-12-210001816581oust:ColonnadeAcquisitionCorpMemberoust:CLAWarrantsMember2020-12-210001816581oust:ColonnadeAcquisitionCorpMemberoust:ConversionOfWarrantToOusterCommonStockMember2020-12-210001816581oust:ColonnadeAcquisitionCorpMemberoust:ConversionOfCanceledCLAUnitsToOusterCommonStockMember2020-12-210001816581oust:PrivatePlacementWarrantsMemberoust:ColonnadeAcquisitionCorpMember2020-12-210001816581us-gaap:SeriesBPreferredStockMemberoust:OusterTechnologiesIncMember2021-03-100001816581oust:SeriesBPreferredStockConvertedToCommonStockMemberoust:OusterTechnologiesIncMember2021-03-100001816581oust:OusterTechnologiesIncMember2021-03-100001816581us-gaap:CommonStockMember2021-03-112021-03-1100018165812021-03-1100018165812021-03-112021-03-110001816581us-gaap:PrivatePlacementMember2020-12-212020-12-210001816581us-gaap:PrivatePlacementMember2020-12-210001816581us-gaap:PrivatePlacementMember2021-03-112021-03-110001816581oust:ColonnadeAcquisitionCorpMemberoust:ConversionOfCanceledCLAUnitsToPublicWarrantMember2020-12-210001816581oust:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001816581oust:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001816581oust:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001816581oust:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001816581oust:OneSupplierMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMember2021-01-012021-03-310001816581oust:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2021-01-012021-03-310001816581oust:OneSupplierMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMember2022-01-012022-03-310001816581oust:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2021-01-012021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMember2022-03-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001816581us-gaap:FairValueMeasurementsRecurringMember2021-12-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-03-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-03-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2020-12-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2020-12-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001816581oust:RedeemableConvertiblePreferredStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-03-310001816581oust:PrivatePlacementWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-03-310001816581us-gaap:MachineryAndEquipmentMember2022-01-012022-03-310001816581us-gaap:MachineryAndEquipmentMember2022-03-310001816581us-gaap:MachineryAndEquipmentMember2021-12-310001816581us-gaap:ComputerEquipmentMember2022-01-012022-03-310001816581us-gaap:ComputerEquipmentMember2022-03-310001816581us-gaap:ComputerEquipmentMember2021-12-310001816581us-gaap:VehiclesMember2022-01-012022-03-310001816581us-gaap:VehiclesMember2022-03-310001816581us-gaap:VehiclesMember2021-12-310001816581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-012022-03-310001816581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-03-310001816581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001816581us-gaap:FurnitureAndFixturesMember2022-01-012022-03-310001816581us-gaap:FurnitureAndFixturesMember2022-03-310001816581us-gaap:FurnitureAndFixturesMember2021-12-310001816581us-gaap:ConstructionInProgressMember2022-03-310001816581us-gaap:ConstructionInProgressMember2021-12-310001816581us-gaap:LeaseholdImprovementsMember2022-03-310001816581us-gaap:LeaseholdImprovementsMember2021-12-310001816581us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-03-310001816581us-gaap:TechnologyBasedIntangibleAssetsMember2022-03-310001816581oust:VendorRelationshipMember2022-01-012022-03-310001816581oust:VendorRelationshipMember2022-03-310001816581us-gaap:CustomerRelationshipsMember2022-01-012022-03-310001816581us-gaap:CustomerRelationshipsMember2022-03-310001816581us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-310001816581us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001816581oust:VendorRelationshipMember2021-01-012021-12-310001816581oust:VendorRelationshipMember2021-12-310001816581us-gaap:CustomerRelationshipsMember2021-01-012021-12-310001816581us-gaap:CustomerRelationshipsMember2021-12-310001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMember2018-11-270001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2018-11-272018-11-270001816581us-gaap:SecuredDebtMemberus-gaap:PrimeRateMemberoust:RunwayLoanAndSecurityAgreementMemberoust:LIBORRateNotAvailableOrApplicableMember2018-11-272018-11-270001816581us-gaap:SecuredDebtMemberoust:InTheEventOfDebtDefaultMemberoust:RunwayLoanAndSecurityAgreementMemberoust:ApplicableInterestRateAtTheTimeOfDefaultMember2022-01-012022-03-310001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMember2021-03-310001816581oust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2018-11-270001816581oust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2019-08-050001816581oust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2019-08-052019-08-050001816581us-gaap:OtherNonoperatingIncomeExpenseMemberoust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2021-01-012021-03-310001816581oust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2021-01-012021-03-310001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMember2021-03-262021-03-260001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMember2021-12-310001816581us-gaap:SecuredDebtMemberoust:RunwayLoanAndSecurityAgreementMember2022-03-310001816581us-gaap:InvestorMemberoust:PromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMember2021-01-310001816581us-gaap:InvestorMemberoust:PromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMember2021-01-012021-01-310001816581oust:OusterTechnologiesIncMemberoust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2018-11-270001816581oust:OusterTechnologiesIncMemberoust:SeriesARedeemableConvertiblePreferredStockWarrantsMember2019-08-050001816581oust:OusterTechnologiesIncMemberoust:SeriesBRedeemableConvertiblePreferredStockWarrantsMember2020-04-030001816581srt:MaximumMemberoust:OusterTechnologiesIncMemberoust:SeriesBRedeemableConvertiblePreferredStockWarrantsMember2020-04-030001816581oust:OusterTechnologiesIncMemberoust:SeriesBRedeemableConvertiblePreferredStockWarrantsMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-03-310001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMemberoust:OusterTechnologiesIncMember2018-11-270001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMemberoust:OusterTechnologiesIncMember2020-04-030001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMemberoust:OusterTechnologiesIncMember2020-12-310001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMemberoust:OusterTechnologiesIncMember2021-02-110001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMemberoust:OusterTechnologiesIncMember2021-03-110001816581us-gaap:MeasurementInputExpectedTermMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2018-11-27oust:year0001816581us-gaap:MeasurementInputExpectedTermMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-04-030001816581us-gaap:MeasurementInputExpectedTermMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-12-310001816581us-gaap:MeasurementInputExpectedTermMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-02-110001816581us-gaap:MeasurementInputExpectedTermMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-03-110001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2018-11-270001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-04-030001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-12-310001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-02-110001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-03-110001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2018-11-270001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-04-030001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2020-12-310001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-02-110001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberoust:OusterTechnologiesIncMember2021-03-110001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMemberoust:OusterTechnologiesIncMember2018-11-270001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMemberoust:OusterTechnologiesIncMember2020-04-030001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMemberoust:OusterTechnologiesIncMember2020-12-310001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMemberoust:OusterTechnologiesIncMember2021-02-110001816581oust:RedeemableConvertiblePreferredStockWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMemberoust:OusterTechnologiesIncMember2021-03-110001816581oust:PrivatePlacementWarrantsMemberoust:SponsorMember2020-08-310001816581oust:PrivatePlacementWarrantsMemberoust:SponsorMember2020-08-012020-08-310001816581oust:PrivatePlacementWarrantsMember2020-08-310001816581oust:PrivatePlacementWarrantsMemberoust:SponsorMemberoust:ConversionOfWarrantToOusterCommonStockMember2021-03-110001816581oust:PrivatePlacementWarrantsMemberoust:SponsorMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-03-310001816581oust:PrivatePlacementWarrantsMemberoust:SponsorMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-03-310001816581oust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMember2021-03-110001816581oust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMember2021-03-310001816581oust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001816581oust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputSharePriceMember2022-03-310001816581us-gaap:MeasurementInputExercisePriceMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-110001816581us-gaap:MeasurementInputExercisePriceMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-310001816581us-gaap:MeasurementInputExercisePriceMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-12-310001816581us-gaap:MeasurementInputExercisePriceMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-03-310001816581us-gaap:MeasurementInputExpectedTermMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-110001816581us-gaap:MeasurementInputExpectedTermMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-310001816581us-gaap:MeasurementInputExpectedTermMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-12-310001816581us-gaap:MeasurementInputExpectedTermMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-03-310001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-110001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-310001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-12-310001816581us-gaap:MeasurementInputPriceVolatilityMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-03-310001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-110001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-03-310001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2021-12-310001816581us-gaap:MeasurementInputRiskFreeInterestRateMemberoust:PrivatePlacementWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-03-310001816581oust:ColonnadeAcquisitionCorpMemberoust:PublicWarrantsMember2020-08-310001816581oust:PublicWarrantsMember2020-08-012020-08-310001816581oust:PublicWarrantsMember2020-08-310001816581oust:PublicWarrantsMember2021-03-110001816581oust:ThirdPartyContractManufacturerMember2022-03-310001816581oust:OtherVendorsMember2022-03-31oust:vote0001816581us-gaap:RedeemableConvertiblePreferredStockMemberoust:OusterTechnologiesIncMember2021-03-10oust:plan0001816581oust:ManagementAndEmployeeMemberoust:ConvertiblePromissoryNoteMemberus-gaap:NotesPayableOtherPayablesMember2020-10-120001816581oust:ManagementAndEmployeeMemberoust:A2015StockPlanMember2020-10-122020-10-120001816581oust:ManagementAndEmployeeCertainExecutivesMember2021-03-012021-03-310001816581oust:ManagementAndEmployeeCertainExecutivesMemberoust:A2015StockPlanMember2022-01-012022-03-3100018165812021-01-012021-12-310001816581oust:ExercisePriceRangeOneMember2022-01-012022-03-310001816581oust:ExercisePriceRangeOneMember2022-03-310001816581oust:ExercisePriceRangeTwoMember2022-01-012022-03-310001816581oust:ExercisePriceRangeTwoMember2022-03-310001816581oust:ExercisePriceRangeThreeMember2022-01-012022-03-310001816581oust:ExercisePriceRangeThreeMember2022-03-310001816581oust:ExercisePriceRangeFourMember2022-01-012022-03-310001816581oust:ExercisePriceRangeFourMember2022-03-310001816581oust:ExercisePriceRangeFiveMember2022-01-012022-03-310001816581oust:ExercisePriceRangeFiveMember2022-03-310001816581oust:ExercisePriceRangeSixMember2022-01-012022-03-310001816581oust:ExercisePriceRangeSixMember2022-03-310001816581us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001816581us-gaap:RestrictedStockUnitsRSUMember2021-12-310001816581us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001816581us-gaap:RestrictedStockUnitsRSUMember2022-03-310001816581us-gaap:CostOfSalesMember2022-01-012022-03-310001816581us-gaap:CostOfSalesMember2021-01-012021-03-310001816581us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001816581us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001816581us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001816581us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001816581us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001816581us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001816581us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001816581us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001816581us-gaap:RestrictedStockMember2022-01-012022-03-310001816581us-gaap:RestrictedStockMember2021-01-012021-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsToPurchaseCommonStockMember2022-01-012022-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsToPurchaseCommonStockMember2021-01-012021-03-310001816581oust:PublicAndPrivateCommonStockWarrantsMember2022-01-012022-03-310001816581oust:PublicAndPrivateCommonStockWarrantsMember2021-01-012021-03-310001816581us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001816581us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEarlyExercisedCommonStockOptionsMember2022-01-012022-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedEarlyExercisedCommonStockOptionsMember2021-01-012021-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedRestrictedStockAwardMember2022-01-012022-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedRestrictedStockAwardMember2021-01-012021-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEarlyExercisedOptionsSubjectToNonrecourseNotesMember2022-01-012022-03-310001816581oust:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEarlyExercisedOptionsSubjectToNonrecourseNotesMember2021-01-012021-03-310001816581us-gaap:TransferredAtPointInTimeMemberoust:LidarSensorKitsMember2022-01-012022-03-310001816581us-gaap:TransferredAtPointInTimeMemberoust:LidarSensorKitsMember2021-01-012021-03-310001816581country:US2022-01-012022-03-310001816581country:US2021-01-012021-03-310001816581oust:AmericasExcludingUnitedStatesMember2022-01-012022-03-310001816581oust:AmericasExcludingUnitedStatesMember2021-01-012021-03-310001816581srt:AsiaPacificMember2022-01-012022-03-310001816581srt:AsiaPacificMember2021-01-012021-03-310001816581us-gaap:EMEAMember2022-01-012022-03-310001816581us-gaap:EMEAMember2021-01-012021-03-310001816581oust:HerculesLoanAndSecurityAgreementMemberus-gaap:SubsequentEventMemberoust:TermLoanMember2022-04-290001816581oust:HerculesLoanAndSecurityAgreementMemberus-gaap:PrimeRateMemberus-gaap:SubsequentEventMemberoust:TermLoanMembersrt:MinimumMember2022-04-292022-04-290001816581oust:HerculesLoanAndSecurityAgreementMemberus-gaap:SubsequentEventMemberoust:TermLoanMember2022-04-292022-04-290001816581oust:HerculesLoanAndSecurityAgreementMemberoust:DebtInstrumentAdditionalBorrowingCapacityScenarioOneMemberus-gaap:SubsequentEventMemberoust:TermLoanMember2022-04-290001816581oust:HerculesLoanAndSecurityAgreementMemberus-gaap:SubsequentEventMemberoust:TermLoanMemberoust:DebtInstrumentAdditionalBorrowingCapacityScenarioTwoMember2022-04-290001816581oust:AtTheMarketProgramMemberus-gaap:SubsequentEventMember2022-04-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 |
For the quarterly period ended
March 31, 2022
OR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 |
For the transition period from
to
Commission File Number: 001-39463
_______________________
Ouster, Inc.
(Exact name of registrant as specified in its charter)
_______________________
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
|
|
86-2528989
|
(State or other jurisdiction
of incorporation)
|
|
|
|
(I.R.S. Employer
Identification No.)
|
350 Treat Avenue
San Francisco, California 94110
(Address of principal executive offices) (Zip Code)
(415) 949-0108
(Registrant’s telephone number, including area code)
N/A
(Former name, former address, and former fiscal year, if changed
since last report)
_______________________
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.0001 par value per share |
|
OUST |
|
New York Stock Exchange |
Warrants to purchase common stock |
|
OUST WS |
|
New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing
requirements for the past 90
days. Yes ☒
No ☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer |
☒ |
Accelerated filer |
☐ |
Non-accelerated filer |
☐ |
Smaller reporting company |
☐ |
Emerging growth company |
☐ |
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a s›hell company
(as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒
As of May 5, 2022, the registrant had 173,664,057 shares of
common stock, $0.0001 par value per share,
outstanding.
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Part II - Other Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.
Ouster, Inc. (the “Company” or “Ouster”) intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”).
All statements contained in this Quarterly Report on Form 10-Q
other than statements of historical fact, including statements
regarding Ouster’s future operating results and financial position,
its business strategy and plans, potential acquisitions, market
growth and trends, and its objectives for future operations, are
forward-looking statements. The words “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,”
“would,” “project,” “plan,” “potentially,” “preliminary,” “likely,”
and similar expressions are intended to identify forward-looking
statements. The Company has based these forward-looking statements
largely on its current expectations and projections about future
events and trends that it believes may affect its financial
condition, results of operations, business strategy, short-term and
long-term business operations and objectives, and financial needs.
These forward-looking statements are subject to a number of risks,
uncertainties, and assumptions, including Ouster’s limited
operating history and history of losses; the negotiating power and
product standards of its customers; fluctuations in its operating
results; cancellation or postponement of contracts or unsuccessful
implementations; the adoption of its products and the growth of the
lidar market generally; its ability to grow its sales and marketing
organization; substantial research and development costs needed to
develop and commercialize new products; the competitive environment
in which it operates; selection of its products for inclusion in
target markets; its future capital needs; its ability to use tax
attributes; its dependence on key third party suppliers, in
particular Benchmark Electronics, Inc., and manufacturers; its
ability to maintain inventory and the risk of inventory
write-downs; inaccurate forecasts of market growth; its ability to
manage growth; the creditworthiness of its customers; risks related
to acquisitions; risks related to international operations; risks
of product delivery problems or defects; costs associated with
product warranties; its ability to maintain competitive average
selling prices or high sales volumes or reduce product costs;
conditions in its customers industries; its ability to recruit and
retain key personnel; its use of professional employer
organizations; its ability to adequately protect and enforce its
intellectual property rights; its ability to effectively respond to
evolving regulations and standards; risks related to operating as a
public company; risks related to the COVID-19 pandemic; and risks
related to certain of its warrants being accounted for as
liabilities. Other risk factors include the important factors
described in the Company’s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the “SEC”) on February 28,
2022, that may cause its actual results, performance or
achievements to differ materially and adversely from those
expressed or implied by the forward-looking
statements.
Any forward-looking statements made herein speak only as of the
date of this Quarterly Report on Form 10-Q, and you should not rely
on forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, performance, or achievements reflected in the
forward-looking statements will be achieved or occur. Except as
required by applicable law, we undertake no obligation to update
any of these forward-looking statements for any reason after the
date of this Quarterly Report on Form 10-Q or to conform these
statements to actual results or revised expectations.
GENERAL
Unless the context otherwise indicates, references in this
Quarterly Report on Form 10-Q to the terms “Ouster,” “the Company,”
“we,” “our” and “us” refer to Ouster, Inc.
We may announce material business and financial information to our
investors using our investor relations website at
https://investors.ouster.com/overview. We therefore encourage
investors and others interested in Ouster to review the information
that we make available on our website, in addition to following our
SEC filings, webcasts, press releases and conference calls.
Information contained on our website is not part of this Quarterly
Report on Form 10-Q.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
OUSTER, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
160,783 |
|
|
$ |
182,644 |
|
Restricted cash, current |
977 |
|
|
977 |
|
Accounts receivable, net |
9,881 |
|
|
10,723 |
|
Inventory |
11,619 |
|
|
7,448 |
|
Prepaid expenses and other current assets |
3,006 |
|
|
5,566 |
|
Total current assets |
186,266 |
|
|
207,358 |
|
Property and equipment, net |
8,968 |
|
|
10,054 |
|
Operating lease, right-of-use assets |
14,582 |
|
|
15,156 |
|
Goodwill |
51,076 |
|
|
51,076 |
|
Intangible assets, net |
21,530 |
|
|
22,652 |
|
Restricted cash, non-current |
1,035 |
|
|
1,035 |
|
Other non-current assets |
452 |
|
|
371 |
|
Total assets |
$ |
283,909 |
|
|
$ |
307,702 |
|
Liabilities, redeemable convertible preferred stock and
stockholders’ equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
9,469 |
|
|
$ |
4,863 |
|
Accrued and other current liabilities |
11,789 |
|
|
14,173 |
|
Operating lease liability, current portion |
2,888 |
|
|
3,067 |
|
Total current liabilities |
24,146 |
|
|
22,103 |
|
Operating lease liability, long-term portion |
15,685 |
|
|
16,208 |
|
Warrant liabilities (At March 31, 2022 and December 31, 2021
related party $2,058 and $2,669, respectively)
|
5,881 |
|
|
7,626 |
|
Other non-current liabilities |
1,018 |
|
|
1,065 |
|
Total liabilities |
46,730 |
|
|
47,002 |
|
Commitments and contingencies (Note 7) |
|
|
|
Redeemable convertible preferred stock, $0.0001 par value per
share; 100,000,000 shares authorized at March 31, 2022 and
December 31, 2021; Nil shares issued and outstanding at
March 31, 2022 and December 31, 2021, respectively
(aggregate liquidation preference of nil at March 31, 2022 and
December 31, 2021, respectively)
|
— |
|
|
— |
|
Stockholders’ equity: |
|
|
|
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at
March 31, 2022 and December 31, 2021, respectively;
173,602,503 and 172,200,417 shares issued and outstanding at
March 31, 2022 and December 31, 2021,
respectively
|
17 |
|
|
17 |
|
Additional paid-in capital |
572,933 |
|
|
564,045 |
|
Accumulated deficit |
(335,753) |
|
|
(303,356) |
|
Accumulated other comprehensive loss |
(18) |
|
|
(6) |
|
Total stockholders’ equity |
237,179 |
|
|
260,700 |
|
Total liabilities, redeemable convertible preferred stock, and
stockholders’ equity |
$ |
283,909 |
|
|
$ |
307,702 |
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS
(unaudited)
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
|
|
|
|
Product revenue |
$ |
8,558 |
|
|
$ |
6,611 |
|
|
|
|
|
|
|
|
|
Cost of product revenue |
5,967 |
|
|
4,868 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
2,591 |
|
|
1,743 |
|
Operating expenses: |
|
|
|
Research and development |
15,906 |
|
|
4,712 |
|
Sales and marketing |
7,090 |
|
|
3,426 |
|
General and administrative |
13,783 |
|
|
9,907 |
|
Total operating expenses |
36,779 |
|
|
18,045 |
|
Loss from operations |
(34,188) |
|
|
(16,302) |
|
Other (expense) income: |
|
|
|
Interest income |
154 |
|
|
1 |
|
Interest expense |
— |
|
|
(504) |
|
Other income (expense), net |
1,684 |
|
|
(4,152) |
|
Total other expense, net |
1,838 |
|
|
(4,655) |
|
Loss before income taxes |
(32,350) |
|
|
(20,957) |
|
Provision for income tax expense |
47 |
|
|
— |
|
Net loss |
$ |
(32,397) |
|
|
$ |
(20,957) |
|
Other comprehensive loss |
|
|
|
Foreign currency translation adjustments |
$ |
(12) |
|
|
— |
|
Total comprehensive loss |
$ |
(32,409) |
|
|
$ |
(20,957) |
|
Net loss per common share, basic and diluted |
$ |
(0.19) |
|
|
$ |
(0.38) |
|
Weighted-average shares used to compute basic and diluted net loss
per share |
170,906,196 |
|
|
55,688,281 |
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(DEFICIT)
(unaudited)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable Convertible
Preferred Stock |
|
Common Stock |
|
Additional
Paid-in-
Capital |
|
Accumulated
Deficit |
|
Accumulated other comprehensive loss |
|
Total
Stockholders’ Equity |
|
Shares
(1)
|
|
Amount |
|
Shares
(1)
|
|
Amount |
|
|
|
|
Balance — December 31, 2021 |
— |
|
|
$ |
— |
|
|
172,200,417 |
|
|
$ |
17 |
|
|
$ |
564,045 |
|
|
$ |
(303,356) |
|
|
$ |
(6) |
|
|
$ |
260,700 |
|
Issuance of common stock upon exercise of stock options |
— |
|
|
— |
|
|
822,702 |
|
|
— |
|
|
209 |
|
|
— |
|
|
— |
|
|
209 |
|
Issuance of common stock upon exercise of restricted stock awards -
net of tax withholding |
— |
|
|
— |
|
|
812,491 |
|
|
— |
|
|
(59) |
|
|
— |
|
|
— |
|
|
(59) |
|
Repurchase of common stock |
— |
|
|
— |
|
|
(233,107) |
|
|
— |
|
|
(31) |
|
|
— |
|
|
— |
|
|
(31) |
|
Stock-based compensation expense |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
8,750 |
|
|
— |
|
|
— |
|
|
8,750 |
|
Vesting of early exercised stock options |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
19 |
|
|
— |
|
|
— |
|
|
19 |
|
Net loss |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(32,397) |
|
|
— |
|
|
(32,397) |
|
Other Comprehensive loss |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(12) |
|
|
(12) |
|
Balance — March 31, 2022 |
— |
|
|
$ |
— |
|
|
173,602,503 |
|
|
$ |
17 |
|
|
$ |
572,933 |
|
|
$ |
(335,753) |
|
|
$ |
(18) |
|
|
$ |
237,179 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable Convertible
Preferred Stock |
|
Common Stock |
|
Additional
Paid-in-
Capital |
|
Accumulated
Deficit |
|
Accumulated other comprehensive loss |
|
Total
Stockholders’ Equity
(Deficit) |
|
Shares
(1)
|
|
Amount |
|
Shares
(1)
|
|
Amount |
|
|
|
|
Balance — December 31, 2020 |
88,434,754 |
|
|
$ |
39,225 |
|
|
33,327,294 |
|
|
$ |
— |
|
|
$ |
133,468 |
|
|
$ |
(209,375) |
|
|
$ |
— |
|
|
$ |
(75,907) |
|
Issuance of common stock upon exercise of stock options |
— |
|
|
— |
|
|
727,114 |
|
|
1 |
|
|
189 |
|
|
— |
|
|
— |
|
|
190 |
|
Repurchase of common stock |
— |
|
|
— |
|
|
(220,561) |
|
|
— |
|
|
(43) |
|
|
— |
|
|
— |
|
|
(43) |
|
Issuance of redeemable convertible preferred stock upon exercise of
warrants |
4,232,947 |
|
|
58,097 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Conversion of redeemable convertible preferred stock to common
stock |
(92,667,701) |
|
|
(97,322) |
|
|
92,667,701 |
|
|
12 |
|
|
97,322 |
|
|
— |
|
|
— |
|
|
97,334 |
|
Issuance of common stock upon merger and private offering, net of
acquired private placement warrants of $19,377
|
— |
|
|
— |
|
|
34,947,657 |
|
|
3 |
|
|
272,061 |
|
|
— |
|
|
— |
|
|
272,064 |
|
Offering costs in connection with the merger |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(26,620) |
|
|
— |
|
|
— |
|
|
(26,620) |
|
Stock-based compensation expense |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
5,256 |
|
|
— |
|
|
— |
|
|
5,256 |
|
Vesting of early exercised stock options |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
438 |
|
|
— |
|
|
— |
|
|
438 |
|
Net loss |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(20,957) |
|
|
— |
|
|
(20,957) |
|
Balance — March 31, 2021 |
— |
|
|
$ |
— |
|
|
161,449,205 |
|
|
$ |
16 |
|
|
$ |
482,071 |
|
|
$ |
(230,332) |
|
|
$ |
— |
|
|
$ |
251,755 |
|
(1) The shares of the Company’s common and redeemable convertible
preferred stock, prior to the Merger (as defined in Note 1), have
been retroactively restated as shares reflecting the exchange ratio
of approximately 0.703 established in the Merger as described in
Note 1.
The accompanying notes are an integral part of these condensed
consolidated financial statements.
OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
Net loss |
$ |
(32,397) |
|
|
$ |
(20,957) |
|
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
Depreciation and amortization |
2,385 |
|
|
1,095 |
|
Stock-based compensation |
8,750 |
|
|
5,256 |
|
|
|
|
|
Change in right-of-use asset |
644 |
|
|
520 |
|
Interest expense on notes and convertible debt |
— |
|
|
36 |
|
Amortization of debt issuance costs and debt discount |
— |
|
|
250 |
|
Change in fair value of warrant liabilities |
(1,745) |
|
|
4,152 |
|
|
|
|
|
|
|
|
|
Inventory write down |
203 |
|
|
— |
|
Gain from disposal of property and equipment |
(100) |
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable |
842 |
|
|
(140) |
|
Inventory |
(4,373) |
|
|
(476) |
|
Prepaid expenses and other assets |
2,480 |
|
|
(1,202) |
|
Accounts payable |
4,807 |
|
|
(1) |
|
Accrued and other liabilities |
(2,551) |
|
|
(254) |
|
Operating lease liability |
(772) |
|
|
(678) |
|
Net cash used in operating activities |
(21,827) |
|
|
(12,399) |
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
Proceeds from sale of property and equipment |
275 |
|
|
— |
|
Purchases of property and equipment |
(416) |
|
|
(597) |
|
Net cash used in investing activities |
(141) |
|
|
(597) |
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
Proceeds from the merger and private offering |
— |
|
|
291,454 |
|
Payment of offering costs |
— |
|
|
(26,116) |
|
|
|
|
|
Repayment of debt |
— |
|
|
(7,000) |
|
Proceeds from issuance of promissory notes to related
parties |
— |
|
|
5,000 |
|
Repayment of promissory notes to related parties |
— |
|
|
(5,000) |
|
Repurchase of common stock |
(31) |
|
|
(43) |
|
Proceeds from exercise of stock options |
209 |
|
|
504 |
|
Taxes paid related to net share settlement of equity
awards |
(59) |
|
|
— |
|
Net cash provided by financing activities |
119 |
|
|
258,799 |
|
Effect of exchange rates on cash and cash equivalents |
(12) |
|
|
— |
|
Net increase (decrease) in cash, cash equivalents and restricted
cash |
(21,861) |
|
|
245,803 |
|
Cash, cash equivalents and restricted cash at beginning of
period |
184,656 |
|
|
12,642 |
|
Cash, cash equivalents and restricted cash at end of
period |
$ |
162,795 |
|
|
$ |
258,445 |
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
Cash paid for interest |
$ |
— |
|
|
$ |
635 |
|
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING
INFORMATION: |
|
|
|
Property and equipment purchases included in accounts payable and
accrued liabilities |
$ |
377 |
|
|
$ |
100 |
|
Private placement warrants acquired as part of the
merger |
$ |
— |
|
|
$ |
19,377 |
|
Issuance of redeemable convertible preferred stock upon exercise of
warrants |
$ |
— |
|
|
$ |
58,097 |
|
Conversion of redeemable convertible preferred stock to common
stock |
$ |
— |
|
|
$ |
97,322 |
|
Offering costs not yet paid |
$ |
— |
|
|
$ |
504 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements.
OUSTER, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Note 1 – Description of Business and Basis of
Presentation
Description of Business
Ouster, Inc. was incorporated in the state of Delaware on June 4,
2020. The Company’s operating subsidiary, Ouster Technologies, Inc.
(“OTI” and prior to the Merger (as defined below), named Ouster,
Inc.), was incorporated in the state of Delaware on June 30, 2015.
The Company is a leading provider of high-resolution digital lidar
sensors that offer advanced 3D vision to machinery, vehicles,
robots, and fixed infrastructure assets, allowing each to
understand and visualize the surrounding world and ultimately
enabling safe operation and ubiquitous autonomy. Unless the context
otherwise requires, references in this subsection to “the Company”
refer to the business and operations of OTI (formerly known as
Ouster, Inc.) and its consolidated subsidiaries prior to the Merger
(as defined below) and to Ouster, Inc. (formerly known as Colonnade
Acquisition Corp.) and its consolidated subsidiaries following the
consummation of the Merger.
Colonnade Acquisition Corp. (“CLA”), the Company’s legal
predecessor, was originally a blank check company incorporated as a
Cayman Islands exempted company on June 4, 2020. CLA was formed for
the purpose of effecting a merger, share exchange, asset
acquisition, share purchase, reorganization or similar business
combination with one or more businesses. On March 11, 2021, CLA
consummated a merger with the Company pursuant to an Agreement and
Plan of Merger (the “Merger Agreement”) dated as of December 21,
2020, details of which are included below.
Basis of Presentation and Principles of Consolidation
The unaudited condensed consolidated financial statements include
the accounts of the Company and its subsidiaries (all of which are
wholly owned) and have been prepared in conformity with U.S.
generally accepted accounting principles (“US GAAP”) applicable to
interim periods. The functional currency for the Company is the
United States dollar. All intercompany balances and transactions
have been eliminated in consolidation.
The unaudited condensed consolidated financial statements include
all adjustments (consisting of only normal recurring adjustments)
necessary for a fair statement of the results of operations for the
periods shown. The unaudited condensed consolidated financial
statements should be read in conjunction with the Company’s audited
consolidated financial statements as of and for the year ended
December 31, 2021 and the notes related thereto, included in the
Company’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission (“SEC”) on February 28, 2022. The year-end
condensed balance sheet data was derived from audited financial
statements, but does not include all disclosures required by US
GAAP. Certain information and note disclosures normally included in
the audited financial statements prepared in accordance with US
GAAP have been condensed or omitted from this report, as is
permitted by such rules and regulations. The results of operations
for any interim period are not necessarily indicative of the
results to be expected for the year ending December 31, 2022 or for
any other future years or interim periods.
Impact of the COVID-19 Pandemic
Ouster has been actively monitoring the COVID-19 pandemic on a
global scale and continues to evaluate the long-term impacts on the
business while keeping abreast of the latest developments,
particularly the variants of the virus, to ensure preparedness for
Ouster’s employees and its business. We maintain our commitment to
protect the health and safety of our employees and customers. We
continue to adapt and enhance our safety protocols as we follow the
guidance from local authorities. The full extent to which the
COVID-19 pandemic will directly or indirectly impact the Company’s
business, results of operations and financial condition, including
sales, expenses, reserves and allowances, manufacturing, research
and development costs and employee-related amounts, will depend on
future events that are by nature uncertain, including as a result
of new information that continues to emerge concerning the virus,
its variants, the deployment and effectiveness of vaccination
roll-outs, vaccination hesitancy, and the actions taken to contain
the virus or treat it, as well as the economic impact on local,
regional, national and international customers and markets. Thus,
the Company is not able to estimate the future consequences on its
operations, its financial condition, or its liquidity.
Liquidity
The accompanying unaudited condensed consolidated financial
statements have been prepared on a going concern basis. The Company
has experienced recurring losses from operations, and negative cash
flows from operations. As of March 31, 2022, the Company had
an accumulated deficit of approximately $335.8 million. The Company
has historically financed its operations primarily through the
Merger and related transactions, the sale of convertible notes,
equity securities, proceeds from debt and, to a lesser extent, cash
received from sales. Management expects significant operating
losses and negative cash flows from operations to continue for the
foreseeable future. The Company expects to continue investing in
product development and sales and marketing activities. The
long-term continuation of the Company’s business plan is dependent
upon the generation of sufficient revenues from its products to
offset expenses. In the event that the Company does not generate
sufficient cash flows from operations and is unable to obtain
funding, the Company will be forced to delay, reduce, or eliminate
some or all of its discretionary spending, which could adversely
affect the Company’s business prospects, ability to meet long-term
liquidity needs or ability to continue operations. The Company has
concluded that its cash and cash equivalents as of March 31,
2022 are sufficient for the Company to continue as a going concern
for at least one year from the date these unaudited condensed
consolidated financial statements are available for
issuance.
Merger Agreement with Colonnade Acquisition Corp. and Beam Merger
Sub, Inc.
On December 21, 2020, OTI entered into the Merger Agreement with
CLA and Beam Merger Sub, Inc. (“Merger Sub”), a Delaware
corporation and subsidiary of CLA. OTI’s board of directors
unanimously approved OTI’s entry into the Merger Agreement, and on
March 11, 2021, the transactions contemplated by the Merger
Agreement were consummated. Pursuant to the terms of the Merger
Agreement, (i) CLA domesticated as a corporation incorporated under
the laws of the State of Delaware and changed its name to “Ouster,
Inc.” and (ii) Merger Sub merged with and into OTI (such
transactions contemplated by the Merger Agreement, the “Merger”),
with OTI surviving the Merger.
As a result of the Merger, among other things, (1) each of the then
issued and outstanding 5,000,000 CLA Class B ordinary shares, par
value $0.0001 per share, of CLA (the “CLA Class B ordinary shares”)
converted automatically, on a one-for-one basis, into a CLA Class A
ordinary share (as defined below), (2) immediately following the
conversion described in clause (1), each of the then issued and
outstanding 25,000,000 Class A ordinary shares, par value $0.0001
per share, of CLA (the “CLA Class A ordinary shares”), converted
automatically, on a one-for-one basis, into a share of common
stock, par value $0.0001 per share, of Ouster (the “Ouster common
stock”), (3) each of the then issued and outstanding 10,000,000
redeemable warrants of CLA (the “CLA warrants”) converted
automatically into a redeemable warrant to purchase one share of
Ouster common stock (the “Public warrants”) pursuant to the Warrant
Agreement, dated August 20, 2020 (the “Warrant Agreement”), between
CLA and Continental Stock Transfer & Trust Company
(“Continental”), as warrant agent, and (4) each of the then issued
and outstanding units of CLA that had not been previously separated
into the underlying CLA Class A ordinary shares and underlying CLA
warrants upon the request of the holder thereof (the “CLA units”),
were cancelled and entitled the holder thereof to one share of
Ouster common stock and one-half of one Public warrant, and (5)
each of the then issued and outstanding 6,000,000 private placement
warrants of CLA (the “Private Placement warrants”) converted
automatically into a Public warrant pursuant to the Warrant
Agreement. No fractional Public warrants were issued upon
separation of the CLA units.
Immediately prior to the effective time of the Merger, (1) each
share of OTI’s Series B Preferred Stock, par value $0.00001 per
share (the “OTI Preferred Stock”), converted into one share of
common stock, par value $0.00001 per share, of OTI (the “OTI common
stock” and, together with OTI Preferred Stock, the “OTI Capital
Stock”) (such conversion, the “OTI Preferred Conversion”) and (2)
all of the outstanding warrants to purchase shares of OTI Capital
Stock were exercised in full or terminated in accordance with their
respective terms (the “OTI Warrant Settlement”).
As a result of and upon the closing of the Merger, among other
things, all shares of OTI Capital Stock (after giving effect to the
OTI Warrant Settlement) outstanding immediately prior to the
closing of the Merger together with shares of OTI common stock
reserved in respect of options to purchase shares of OTI common
stock and restricted shares of OTI common stock (together, the “OTI
Awards”) outstanding immediately prior to the closing of the Merger
that were converted into awards based on Ouster common stock, were
cancelled in exchange for the right to receive, or the reservation
of, an aggregate of 150,000,000 shares of Ouster common stock (at a
deemed value of $10.00 per share), which, in the case of OTI
Awards, were shares underlying awards based on Ouster common stock,
representing a fully-diluted pre-transaction. Upon closing of the
Merger, the Company received gross proceeds of $299.9 million
from the Merger and private offering, offset by $8.5 million
of pre-merger costs relating to CLA and offerings costs of
$26.6 million.
The Merger was accounted for as a reverse recapitalization under US
GAAP. Under this method of accounting, CLA is treated as the
“acquired” company for financial reporting purposes. This
determination is primarily based on OTI stockholders comprising a
relative majority of the voting power of the Company and having the
ability to nominate the members of the board
of directors of the Company after the Merger, OTI’s operations
prior to the Merger comprising the only ongoing operations of the
Company following the Merger, and OTI’s senior management prior to
the Merger comprising a majority of the senior management of the
Company following the Merger. Accordingly, for accounting purposes,
the financial statements of the Company represent a continuation of
the financial statements of OTI with the Merger being treated as
the equivalent of OTI issuing stock for the net assets of CLA,
accompanied by a recapitalization whereby no goodwill or other
intangible assets are recorded. Transactions and balances prior to
the Merger are those of OTI. The shares and net loss per share
available to holders of OTI’s common stock prior to the Merger have
been retroactively restated as shares reflecting the exchange ratio
established in the Merger Agreement.
PIPE Investment
On December 21, 2020, concurrently with the execution of the Merger
Agreement, CLA entered into subscription agreements with certain
institutional and accredited investors (collectively, the “PIPE
Investors”), pursuant to which the PIPE Investors agreed to
purchase, in the aggregate, 10,000,000 shares of Ouster common
stock at $10.00 per share for an aggregate commitment amount of
$100,000,000 (the “PIPE Investment”), a portion of which was funded
by certain affiliates of Colonnade Sponsor LLC, CLA’s sponsor (the
“Sponsor”). The PIPE Investment was consummated substantially
concurrently with the closing of the Merger.
Note 2 – Summary of Significant Accounting Policies
During the three months ended March 31, 2022, there were no
significant changes made to the Company’s significant accounting
policies as disclosed in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2021.
Recently Adopted Accounting Pronouncements
In August 2020, the FASB issued Accounting Standards Update (“ASU”)
No. 2020-06, Debt - Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging - Contracts in
Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06).
ASU 2020-06 simplifies the accounting for convertible debt and
convertible preferred stock by removing the requirements to
separately present certain conversion features in equity. In
addition, the amendments in the ASU also simplify the guidance in
ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own
Equity, by removing certain criteria that must be satisfied in
order to classify a contract as equity, which is expected to
decrease the number of freestanding instruments and embedded
derivatives accounted for as assets or liabilities. Finally, the
amendments revise the guidance on calculating earnings per share,
requiring use of the if-converted method for all convertible
instruments and rescinding an entity’s ability to rebut the
presumption of share settlement for instruments that may be settled
in cash or other assets. The new standard is effective for the
Company for annual periods beginning December 15, 2021. The Company
adopted this ASU as of January 1, 2022 using a modified
retrospective method of transition, which did not have an impact on
its condensed consolidated financial statements and related
disclosures.
Recently Issued Accounting Pronouncements not yet
adopted
The Company considers the applicability and impact of all ASUs.
ASUs not referenced below were assessed and determined to be either
not applicable or are not expected to have a material impact on the
Company’s consolidated financial statements.
In October 2021, the FASB issued ASU 2021-08, Business Combinations
(Topic 805): Accounting for Contract Assets and Contract
Liabilities from Contracts with Customers, which amends ASC 805 to
add contract assets and contract liabilities to the list of
exceptions to the recognition and measurement principles that apply
to business combinations and to require that an entity (acquirer)
recognize and measure contract assets and contract liabilities
acquired in a business combination in accordance with Topic 606.
The amendments in this ASU are effective for fiscal years beginning
after December 15, 2022, including interim periods within those
fiscal years and should be applied prospectively to business
combinations occurring on or after the effective date of the
amendments. Early adoption of the amendments is permitted,
including adoption in an interim period. The Company is currently
evaluating the impact of the adoption of this ASU on the Company’s
consolidated financial statements.
Concentrations of credit risk
Financial instruments that potentially subject the Company to
credit risk consist primarily of cash, cash equivalents, and
restricted cash, and accounts receivable. Cash, cash equivalents
and restricted cash are deposited with federally insured commercial
banks in the United States and at times cash balances may be in
excess of federal insurance limits. The Company generally does not
require collateral or other security deposits for accounts
receivable.
To reduce credit risk, the Company considers customer
creditworthiness, past transaction history with the customer,
current economic industry trends, and changes in customer payment
terms when determining the collectability of specific customer
accounts. Past due balances over 90 days and other higher risk
amounts are reviewed individually for collectability. Based on
management’s assessment, the Company provides for estimated
uncollectible amounts through a charge to earnings and a credit to
valuation allowance. Balances that remain outstanding after the
Company has used reasonable collection efforts are written off
through a charge to the valuation allowance and a credit to
accounts receivable.
Accounts receivable from the Company’s major customers representing
10% or more of total accounts receivable was as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Customer A |
* |
|
11 |
% |
|
|
|
|
|
|
|
|
* Customer accounted for less than 10% of total accounts receivable
in the period.
Revenue from the Company’s major customers representing 10% or more
of total revenue was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
Customer B |
* |
|
28 |
% |
|
|
|
|
* Customer accounted for less than 10% of total revenue in the
period.
Concentrations of supplier risk
One supplier accounted for approximately 31% of total purchases
during the three months ended March 31, 2022 and accounted for
52% of total accounts payable as of March 31, 2022. One
supplier accounted for approximately 17% of total purchases during
the three months ended March 31, 2021 and accounted for 55% of
total accounts payable balance as of December 31,
2021.
Note 3. Fair Value of Financial Instruments
The Company applies the fair value measurement accounting standard
whenever other accounting pronouncements require or permit fair
value measurements. Fair value is defined in the accounting
standard as the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The fair value
hierarchy is based on inputs to valuation techniques that are used
to measure fair value that are either observable or unobservable.
Observable inputs reflect assumptions market participants would use
in pricing an asset or liability based on market data obtained from
independent sources, while unobservable inputs reflect a reporting
entity’s pricing based upon their own market assumptions. The fair
value hierarchy consists of the following three
levels:
•Level
1 - Quoted prices for identical instruments in active
markets.
•Level
2 - Quoted prices for similar instruments in active markets; quoted
prices for identical or similar instruments in markets that are not
active; and model-derived valuations whose inputs are observable or
whose significant value drivers are observable.
•Level
3 - Instruments whose significant value drivers are
unobservable.
On March 31, 2022, the Company’s Level 3 liabilities
consisted of the Private Placement warrant liability. The
determination of the fair value of warrant liability is discussed
in Note 6.
On December 31, 2021, the Company’s Level 3 liabilities
consisted of the redeemable convertible preferred stock warrant
liability. The determination of the fair value of warrant liability
is discussed in Note 6.
The following table provides information by level for the Company’s
assets and liabilities that were measured at fair value on a
recurring basis (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2022 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
Assets |
|
|
|
|
|
|
|
Money market funds |
$ |
152,984 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
152,984 |
|
Total financial assets |
$ |
152,984 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
152,984 |
|
Liabilities |
|
|
|
|
|
|
|
Warrant liabilities |
$ |
— |
|
|
$ |
— |
|
|
$ |
5,881 |
|
|
$ |
5,881 |
|
Total financial liabilities |
$ |
— |
|
|
$ |
— |
|
|
$ |
5,881 |
|
|
$ |
5,881 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
Assets |
|
|
|
|
|
|
|
Money market funds |
$ |
177,513 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
177,513 |
|
Total financial assets |
$ |
177,513 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
177,513 |
|
Liabilities |
|
|
|
|
|
|
|
Warrant liabilities |
$ |
— |
|
|
$ |
— |
|
|
$ |
7,626 |
|
|
$ |
7,626 |
|
Total financial liabilities |
$ |
— |
|
|
$ |
— |
|
|
$ |
7,626 |
|
|
$ |
7,626 |
|
Money market funds are included within Level 1 of the fair
value hierarchy because they are valued using quoted market
prices.
The fair value of the Private Placement warrant liabilities is
based on significant unobservable inputs, which represent
Level 3 measurements within the fair value hierarchy. In
determining the fair value of the warrant liabilities, the Company
used the Black-Scholes option pricing model to estimate the fair
value using unobservable inputs including the expected term,
expected volatility, risk-free interest rate and dividend yield
(see Note 6).
The following table presents a summary of the changes in the fair
value of the Company’s Level 3 financial instruments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable
Convertible
Preferred Stock
Warrant Liability |
|
Private Placement Warrant Liability |
Fair value as of December 31, 2021 |
$ |
— |
|
|
$ |
(7,626) |
|
Change in the fair value included in other income (expense),
net |
— |
|
|
1,745 |
|
Fair value as of March 31, 2022 |
$ |
— |
|
|
$ |
(5,881) |
|
|
|
|
|
|
Redeemable
Convertible
Preferred Stock
Warrant Liability |
|
Private Placement Warrant Liability |
Fair value as of December 31, 2020 |
(49,293) |
|
|
— |
|
Private placement warrant liability acquired as part of the
merger |
— |
|
|
(19,377) |
|
Change in the fair value included in other income (expense),
net |
(8,804) |
|
|
4,652 |
|
Issuance of preferred stock upon exercise of warrants |
58,097 |
|
|
— |
|
Fair value as of March 31, 2021 |
$ |
— |
|
|
$ |
(14,725) |
|
Disclosure of Fair Values
Our financial instruments that are not re-measured at fair value
include accounts receivable, accounts payable, accrued and other
current liabilities, convertible notes and debt. The carrying
values of these financial instruments approximate their fair
values.
Note 4. Balance Sheet Components
Cash and Cash Equivalents
The Company’s cash and cash equivalents consist of the following
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Cash |
$ |
7,799 |
|
|
$ |
5,131 |
|
Cash equivalents: |
|
|
|
Money market funds(1)
|
152,984 |
|
|
177,513 |
|
|
|
|
|
Total cash and cash equivalents |
$ |
160,783 |
|
|
$ |
182,644 |
|
(1)The
Company maintains a cash sweep account which is included in money
market funds as of March 31, 2022. Cash is invested in the
short-term money market funds, which is a cash sweep for uninvested
cash that earns interest.
Restricted Cash
Restricted cash consists of certificates of deposit held by a bank
as security for outstanding letters of credit. The Company had a
restricted cash balance of $2.0 million as of March 31, 2022
and December 31, 2021, respectively, which has been excluded
from the Company’s cash and cash equivalents balances. The Company
presented $1.0 million and $0.3 million of the total amount of
restricted cash within current assets on the condensed consolidated
balance sheets as of March 31, 2022 and March 31, 2021,
respectively. The remaining restricted cash balance of $1.0 million
was included in non-current assets on the condensed consolidated
balance sheets as of March 31, 2022 and March 31, 2021,
respectively.
Reconciliation of cash, cash equivalents and restricted cash as
shown in the condensed consolidated statement of cash flows to the
respective accounts within the condensed consolidated balance sheet
is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, |
|
2022 |
|
2021 |
Cash and cash equivalents |
$ |
160,783 |
|
|
$ |
257,165 |
|
Restricted cash, current |
977 |
|
|
276 |
|
Restricted cash, non-current |
1,035 |
|
|
1,004 |
|
Total cash, cash equivalents and restricted cash |
$ |
162,795 |
|
|
$ |
258,445 |
|
Inventory
Inventory, consisting of material, direct and indirect labor, and
manufacturing overhead, consists of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Raw materials |
$ |
3,288 |
|
|
$ |
2,401 |
|
Work in process |
2,280 |
|
|
1,951 |
|
Finished goods |
6,051 |
|
|
3,096 |
|
Total inventory |
$ |
11,619 |
|
|
$ |
7,448 |
|
Total inventory balance as of March 31, 2022 and
December 31, 2021 includes a write down of $1.8 million and
$1.7 million, respectively, for obsolete, scrap, or returned
inventory. During the three months ended March 31, 2022 and
2021, $0.2 million and nil of inventory write downs were
charged to cost of revenue, respectively.
Prepaid expenses and other current assets
Prepaid expenses and other current assets consist of the following
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Prepaid expenses |
$ |
1,408 |
|
|
$ |
1,970 |
|
Prepaid insurance |
108 |
|
|
1,355 |
|
Receivable from contract manufacturer |
1,343 |
|
|
1,344 |
|
Grant receivable |
— |
|
|
779 |
|
Security deposit |
76 |
|
|
118 |
|
Value-added tax (VAT) receivable |
71 |
|
|
— |
|
Total prepaid and other current assets |
$ |
3,006 |
|
|
$ |
5,566 |
|
Property and Equipment, net
Property and equipment consists of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated Useful Life
(in years) |
|
March 31,
2022 |
|
December 31,
2021 |
Machinery and equipment |
3 |
|
$ |
8,593 |
|
|
$ |
8,404 |
|
Computer equipment |
3 |
|
504 |
|
|
498 |
|
Automotive and vehicle hardware |
5 |
|
93 |
|
|
93 |
|
Software |
3 |
|
104 |
|
|
104 |
|
Furniture and fixtures |
7 |
|
730 |
|
|
730 |
|
Construction in progress |
|
|
1,923 |
|
|
1,700 |
|
Leasehold improvements |
Shorter of useful life or lease term |
|
9,310 |
|
|
9,265 |
|
|
|
|
21,257 |
|
|
20,794 |
|
Less: Accumulated depreciation |
|
|
(12,289) |
|
|
(10,740) |
|
Property and equipment, net |
|
|
$ |
8,968 |
|
|
$ |
10,054 |
|
Depreciation expense associated with property and equipment was
$1.3 million and $1.1 million in the three months ended
March 31, 2022 and 2021, respectively.
Goodwill and Acquired Intangible Assets, Net
In the fourth quarter of 2021, the Company completed the
acquisition of Sense Photonics Inc. (“Sense”), a privately held
lidar technology company for autonomous vehicles. The transaction
has been accounted for as a business combination. The Company
purchased all of the outstanding shares of the capital stock of
Sense and settled all Sense debt for total consideration of $72.8
million. Goodwill represents the excess of the purchase price over
the fair value of the identifiable assets and assumed liabilities
acquired and is primarily attributable to the assembled workforce
and expected synergies at the time of the acquisition. Goodwill is
not deductible for tax purposes. Sense’s revenue and pretax loss
for the period from the
acquisition date of October 22, 2021 to December 31, 2021 and March
31, 2022 were not material. In the three-month period ended
March 31, 2022, the Company did not adjust the preliminary
fair values of acquired assets that were recognized as of
December 31, 2021.
The following tables present acquired intangible assets, net as of
March 31, 2022 and December 31, 2021 (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2022
|
|
Estimated Useful Life
(in years) |
|
Gross Carrying amount |
|
Accumulated Amortization |
|
Net Book Value |
Developed technology |
8 |
|
$ |
15,900 |
|
|
$ |
(828) |
|
|
$ |
15,072 |
|
Vendor relationship |
3 |
|
6,600 |
|
|
(917) |
|
|
5,683 |
|
Customer relationships |
3 |
|
900 |
|
|
(125) |
|
|
775 |
|
Intangible assets, net |
|
|
$ |
23,400 |
|
|
$ |
(1,870) |
|
|
$ |
21,530 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021
|
|
Estimated Useful Life
(in years) |
|
Gross Carrying amount |
|
Accumulated Amortization |
|
Net Book Value |
Developed technology |
8 |
|
$ |
15,900 |
|
|
$ |
(331) |
|
|
$ |
15,569 |
|
Vendor relationship |
3 |
|
6,600 |
|
|
(367) |
|
|
6,233 |
|
Customer relationships |
3 |
|
900 |
|
|
(50) |
|
|
850 |
|
Intangible assets, net |
|
|
$ |
23,400 |
|
|
$ |
(748) |
|
|
$ |
22,652 |
|
Amortization expense was $1.1 million during the three months ended
March 31, 2022.
The following table summarizes estimated future amortization
expense of finite-lived intangible assets-net (in
thousands):
|
|
|
|
|
|
Years: |
Amount |
2022 (the remainder of 2022) |
$ |
3,366 |
|
2023 |
4,488 |
|
2024 |
4,071 |
|
2025 |
1,988 |
|
2026 |
1,988 |
|
Thereafter |
5,629 |
|
Total |
$ |
21,530 |
|
Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
Accrued compensation |
$ |
3,487 |
|
|
$ |
3,229 |
|
Uninvoiced receipts |
7,182 |
|
|
9,835 |
|
Other |
1,120 |
|
|
1,109 |
|
Total accrued and other current liabilities |
$ |
11,789 |
|
|
$ |
14,173 |
|
Note 5. Debt
Runway Growth Loan Agreement
On November 27, 2018, the Company entered into a Loan and
Security Agreement with Runway Growth Credit Fund Inc. (“Runway
Loan and Security Agreement”). The Runway Loan and Security
Agreement provided for loans in an aggregate principal amount up to
$10.0 million with a loan maturity date of November 15, 2021.
The loan carried an interest rate equal to LIBOR plus 8.5%, unless
LIBOR no longer was attainable or ceased to fairly reflect the
costs of the lender, in which case the applicable interest rate
would be Prime Rate plus 6.0%. In an event of default, annual
interest was increased by 5.0% above the otherwise applicable rate.
The loan’s annual effective interest rate was approximately 16.4%
for the three months ended March 31, 2021.
In conjunction with the Runway Loan and Security Agreement, OTI
issued a warrant to purchase 35,348 shares of Series A redeemable
convertible preferred stock (the “Series A Preferred Stock”) of OTI
(4.0% of original principal amount of $10.0 million, divided
by the exercise price), with an exercise price of $11.3518 per
share. The fair value of this warrant was estimated to be
$0.1 million and accounted for as a debt discount. On
August 5, 2019, in connection with the second amendment to the
Runway Loan and Security Agreement, the Company amended the warrant
issued to Runway Growth to increase the number of shares available
to purchase to 53,023 shares of Series A Preferred Stock of OTI.
The aggregate value of the warrants increased by $0.1 million
after the warrant modification.
The warrants were exercised on March 11, 2021 and the warrant
liability was remeasured to fair value with the increase recognized
as a loss of $0.6 million for the three months ended March 31, 2021
within other income (expense), net in the consolidated statements
of operations and comprehensive loss. The warrant liability was
remeasured to fair value as of March 31, 2021 and the
reduction was recognized as a gain of $0.2 million.
On March 26, 2021, the Company terminated the Runway Loan and
Security Agreement and repaid the $7.0 million principal
amount outstanding as well as interest and fees amounting to
$0.4 million. The Company incurred no prepayment fees in
connection with the termination and all liens and security
interests securing the loan made pursuant to the Runway Loan and
Security Agreement were released upon termination. As of
March 31, 2022 and December 31, 2021, the outstanding
principal balance of the loan was nil, respectively.
Promissory notes
The Company issued a $5 million promissory note in January
2021 to certain current investors of the Company (or their
respective affiliates) to help continue to fund the Company’s
ongoing operations through the consummation of the Merger. The note
accrued interest at a rate equal to LIBOR plus 8.5% per annum
and
was repaid on March 11, 2021 in accordance with its terms in
connection with the consummation of the Merger.
Note 6. Warrants
Series A and B Redeemable Convertible Preferred Stock
Warrants
On November 27, 2018, in connection with the execution of the
Runway Loan and Security Agreement, OTI issued a warrant to
purchase 35,348 shares of Series A Preferred Stock of OTI at an
exercise price of $11.3518 per share (the “Runway warrant”). On
August 5, 2019, in connection with the second amendment to the
Runway Loan and Security Agreement, OTI amended the Runway warrant
to increase the number of shares available to purchase to 53,023
shares of Series A Preferred Stock of OTI at an exercise price of
$11.3518 per share.
The Runway warrants included a cashless exercise provision under
which their holders could, in lieu of payment of the exercise price
in cash, surrender the Runway warrant and receive a net amount of
shares based on the fair market value of OTI’s stock at the time of
exercise of the warrants after deduction of the aggregate exercise
price. The Runway warrants contained provisions for adjustment of
the exercise price and number of shares issuable upon the exercise
of the Runway warrants in the event of certain stock dividends,
stock splits, reorganizations, reclassifications, and
consolidations.
The fair value of the warrants issued was recorded as of the date
of initial issuance in the amount of $0.1 million. The
subsequent issuance of warrants pursuant to the August 5, 2019
amendment to the Runway Loan and Security Agreement was recorded in
the amount of $0.1 million. Immediately prior to the Merger,
the warrants were exercised in full in accordance with their
terms.
On April 3, 2020, in connection with the closing of the Series
B redeemable convertible preferred stock, OTI issued a warrant to
purchase 4,513,993 shares of Series B redeemable convertible
preferred stock of the Company at an exercise price of $0.3323 per
share (the “Series B warrants”). The Series B warrants could be
exercised prior to the earliest to occur of (i) the
10-year anniversary of the date of issuance, (ii) the
consummation of a liquidation transaction, or (iii) the
consummation of an initial public offering. The Series B warrants
included a cashless exercise provision under which their holders
may, in lieu of payment of the exercise price in cash, surrender
the warrant and receive a net amount of shares based on the fair
market value of the Company’s stock at the time of exercise of the
warrants after deduction of the aggregate exercise price. The
Series B warrants contained provisions for adjustment of the
exercise price and number of shares issuable upon the exercise of
the Series B warrants in the event of certain stock dividends,
stock splits, reorganizations, reclassifications, and
consolidations.
The Series B warrants were initially recognized as a liability at a
fair value of $0.7 million. The Series B warrants were exercised on
February 11, 2021 and the warrant liability was remeasured to fair
value as of that date, resulting in a loss of $8.3 million for the
three months ended March 31, 2021, classified within other income
(expense), net in the consolidated statements of operations and
comprehensive loss. Upon exercise redeemable convertible preferred
stock converted into common stock pursuant to the conversion rate
effective immediately prior to the Merger.
Historically, value was assigned to each class of equity securities
using an option pricing model method (“OPM”). In September 2020,
OTI began allocating the equity value using a hybrid method that
utilizes a combination of the OPM and the probability weighted
expected return method (“PWERM”). The PWERM is a scenario-based
methodology that estimates the fair value of equity securities
based upon an analysis of future values for OTI, assuming various
outcomes. As the probability of a transaction with a special
purpose acquisition company (“SPAC”) increased, the fair value of
the redeemable convertible preferred stock warrant liability
increased as of the date of the exercise.
The redeemable convertible preferred stock warrants were valued
using the following assumptions under the Black-Scholes
option-pricing model:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial Issuance
Date |
|
Subsequent
Issuance Date |
|
December 31,
2020 |
|
February 11,
2021 |
|
March 11,
2021 |
Stock price |
$ |
5.80 |
|
|
$ |
5.80 |
|
|
$ |
7.11 |
|
|
$ |
10.27 |
|
|
$ |
8.44 |
|
Expected term (years) |
10.00 |
|
9.31 |
|
2.00 |
|
2.00 |
|
2.00 |
Expected volatility |
57.81 |
% |
|
57.35 |
% |
|
76.00 |
% |
|
76.00 |
% |
|
76.00 |
% |
Risk-free interest rate |
3.06 |
% |
|
1.75 |
% |
|
0.13 |
% |
|
0.13 |
% |
|
0.13 |
% |
Dividend yield |
0 |
% |
|
0 |
% |
|
0 |
% |
|
0 |
% |
|
0 |
% |
Private Placement Warrants
Simultaneously with the closing of the Company’s initial public
offering (the “IPO”) in August 2020, the sponsor of CLA, Colonnade
Sponsor LLC, purchased an aggregate of 6,000,000 Private Placement
warrants at a price of $1.00 per warrant, for an aggregate purchase
price of $6,000,000. The Private Placement warrants became
exercisable 12 months following the closing of the Company’s IPO,
and will expire five years from the completion of the Merger, or
earlier upon redemption or liquidation. Each Private Placement
warrant is exercisable for one Class A ordinary share at a price of
$11.50 per share. On March 11, 2021, each outstanding Private
Placement warrant automatically converted into a warrant to
purchase one share of Ouster common stock pursuant to the Warrant
Agreement.
The Private Placement warrants were initially recognized as a
liability at a fair value of $19.4 million and the Private
Placement warrant liability was remeasured to fair value as of
March 31, 2022 and 2021, resulting in a gain of $1.7 million
and $4.6 million for the three months ended March 31, 2022 and
2021, respectively, classified within other income (expense), net
in the condensed consolidated statements of operations and
comprehensive loss.
The Private Placement warrants were valued using the following
assumptions under the Black-Scholes option-pricing
model:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 11, 2021 |
|
March 31,
2021 |
|
December 31,
2021 |
|
March 31,
2022 |
Stock price |
$ |
12.00 |
|
|
$ |
8.50 |
|
|
$ |
5.20 |
|
|
$ |
4.60 |
|
Exercise price of warrant |
$ |
11.50 |
|
|
$ |
11.50 |
|
|
$ |
11.50 |
|
|
$ |
11.50 |
|
Expected term (years) |
5.00 |
|
|
4.95 |
|
|
4.19 |
|
|
3.95 |
|
Expected volatility |
27.00 |
% |
|
43.00 |
% |
|
57.00 |
% |
|
56.81 |
% |
Risk-free interest rate |
0.78 |
% |
|
0.92 |
% |
|
1.14 |
% |
|
2.55 |
% |
|
|
|
|
|
|
|
|
Public Warrants
CLA, in its IPO in August 2020, issued 20,000,000 units that each
consisted one Class A ordinary share and one half warrant to
purchase a Class A ordinary share, which the Company refers to as
CLA warrants before the Merger and Public warrants after the
Merger. These warrants may only be exercised for a whole number of
shares, and no fractional warrants were issued or issuable upon
separation of the units and only whole warrants will trade. The
warrants became exercisable 12 months following the closing of the
Company’s IPO, and will expire five years from the completion of
the Merger, or earlier upon redemption or liquidation. Each Public
warrant is exercisable at a price of $11.50 per share. On March 11,
2021, upon the closing of the Merger pursuant to the Merger
Agreement (Note 1), each of the 9,999,996 outstanding warrants, as
adjusted for any fractional warrants that were not issued upon
separation, was converted automatically into a redeemable Public
warrant to purchase one share of the Company’s common stock. The
Public warrants were recognized as equity upon the Merger in the
amount of $17.9 million.
Prior to their expiration, the Company may redeem the Public
warrants at a price of $0.01 per warrant, provided that the closing
price of the Company’s common stock equals or exceeds $18.00 per
share for any 20 trading days within a 30 trading-day period ending
on the third trading day prior to the date on which the Company
gives proper notice of such redemption to the warrants
holders.
Note 7. Commitments and Contingencies
Letters of credit
In connection with the lease agreements (collectively the “350
Treat Building Lease” and the “2741 16th Street Lease”), the
Company obtained letters of credit from certain banks as required
by the lease agreements. If the Company defaults under the terms of
the applicable lease, the lessor will be entitled to draw upon the
letters of credit in the amount necessary to cure the default. The
amounts covered by the letters of credit are collateralized by
certificates of deposit, which are included in restricted cash on
the condensed consolidated balance sheets as of March 31, 2022
and December 31, 2021. The outstanding amount of the letters
of credit was $2.0 million as of March 31, 2022 and
December 31, 2021.
Non-cancelable purchase commitments
As of March 31, 2022, the Company had non-cancelable purchase
commitments to a third-party contract manufacturer for
approximately $21.3 million and to other vendors for approximately
$9.1 million.
Litigation
On June 10, 2021, the Company received a letter from the SEC
notifying us of an investigation and document subpoena. The
subpoena seeks documents regarding projected financial information
in CLA’s Form S-4 registration statement filed on December 22,
2020. The Company has complied with the SEC’s requests to date;
however, the SEC may request additional documents or information.
Should the SEC pursue this matter further, it could have a material
impact on our business and operations. At this time, we are unable
to estimate the probability or the amount of liability, if any,
related to this matter.
The Company is involved in various legal proceedings arising in the
ordinary course of business. The Company accrues a liability when a
loss is considered probable and the amount can be reasonably
estimated. When a material loss contingency is reasonably possible
but not probable, the Company does not record a liability, but
instead discloses the nature and the amount of the claim, and an
estimate of the loss or range of loss, if such an estimate can be
made. Legal fees are expensed as incurred. Based on the opinion of
legal counsel and other factors, management believes that the final
disposition of these existing matters will not have a material
adverse effect on the business, results of operations, financial
condition, or cash flows of the Company. The Company has identified
certain claims as a result of which a loss may be incurred, but in
the aggregate any loss is expected to be immaterial. This
assessment is based on our current understanding of relevant facts
and circumstances. As such, our view of these matters is subject to
inherent uncertainties and may change in the future. Significant
judgment is required in both the determination of probability and
the determination as to whether an exposure is reasonably
estimable. Actual outcomes of these legal and regulatory
proceedings may materially differ from our current estimates. For
other claims regarding proceedings that are in an initial phase,
the Company is unable to estimate the range of possible loss, if
any, but at this time believes that any loss related to such claims
will not be material.
As of March 31, 2022 and December 31, 2021 there were no
material litigation matters.
Indemnification
From time to time, the Company enters into agreements in the
ordinary course of business that include indemnification
provisions. Generally, in these provisions the Company agrees to
defend, indemnify, and hold harmless the indemnified parties for
claims and losses suffered or incurred by such indemnified parties
for which the Company is responsible under the applicable
indemnification provisions. The terms of the indemnification
provisions vary depending upon negotiations between the Company and
its counterpart; however, typically, these indemnification
obligations survive the term of the contract and the maximum
potential amount of future payments the Company could be required
to make pursuant to these provisions are uncapped. To date, the
Company has never incurred costs to defend lawsuits or settle
claims related to these indemnification provisions.
The Company has also entered into indemnity agreements pursuant to
which it has indemnified its directors and officers, to the extent
legally permissible, against all liabilities reasonably incurred in
connection with any action in which such individual may be involved
by reason of such individual being or having been a director or
executive officer, other than liabilities arising from willful
misconduct of the individual. To date, the Company has never
incurred costs to defend lawsuits or settle claims related to these
indemnity agreements. The unaudited condensed consolidated
financial statements do not include a liability for any potential
obligations under the indemnification agreements at March 31,
2022 and December 31, 2021.
Note 8. Redeemable Convertible Preferred and Common
Stock
The Company’s common stock and warrants trade on the New York Stock
Exchange under the symbol “OUST” and “OUSTWS”, respectively.
Pursuant to the terms of the Second Amended and Restated
Certificate of Incorporation, the Company is authorized and has
available for issuance the following shares and classes of capital
stock, each with a par value of $0.0001 per share: (i)
1,000,000,000 shares of common stock; (ii) 100,000,000 shares of
preferred stock. Immediately following the Merger, there were
161,449,205 shares of common stock with a par value of $0.0001, and
15,999,996 warrants outstanding. The holder of each share of common
stock is entitled to one vote.
The Company has retroactively adjusted the shares issued and
outstanding prior to March 11, 2021 to give effect to the exchange
ratio established in the Merger Agreement to determine the number
of shares of common stock into which they were
converted.
Immediately prior to the Merger, OTI’s certificate of
incorporation, as amended, authorized it to issue 342,367,887
shares of $0.00001 par value, with 210,956,516 shares designated as
common stock and 131,411,372 shares of redeemable convertible
preferred stock.
On March 11, 2021, upon the closing of the Transaction pursuant to
the Merger Agreement (Note 1), all of the outstanding redeemable
convertible preferred stock was converted to the Company’s common
stock pursuant to the conversion rate effective immediately prior
to the Transaction and the remaining amount was reclassified to
additional paid-in capital. As of March 31, 2022 and
December 31, 2021, the Company does not have any redeemable
convertible preferred stock outstanding.
Note 9. Stock-based compensation
As of March 31, 2022, the Company has three equity incentive
plans, the 2015 Stock Plan (the “2015 Plan”), the 2021 Incentive
Award Plan (the “2021 Plan”) and the Sense 2017 Equity Incentive
Plan (the “Sense Plan” and together the “Plans”).
The Plans provide for the grant of stock options, stock
appreciation rights, restricted stock awards (“RSA”), restricted
stock units (“RSU”), performance stock unit awards and other forms
of equity compensation (collectively, “equity awards”). In
addition, the 2021 Plan provides for the grant of performance bonus
awards. All awards within the Plans may be granted to employees,
including officers, as well as directors and consultants, within
the limits defined in the Plans.
Certain employees have the right to early exercise unvested stock
options, subject to rights held by the Company to repurchase
unvested shares in the event of voluntary or involuntary
termination. The Company accounts for cash received in
consideration for the early exercise of unvested stock options as a
non-current liability, included as a component of other liabilities
in the Company’s condensed consolidated balance
sheets.
On October 12, 2020, the Company issued $1.1 million partial
recourse promissory notes to certain executives and employees. The
promissory notes carried 0.38% annual cash interest and were due on
the earliest of 9th anniversary of the date of issuance of the
notes, or termination of employment of the executive/employee, or
filing by the Company of a registration statement under the
Securities Act of 1933, or promissory notes being prohibited under
Section 13(k) of the Securities Exchange Act of 1934 or closing of
change a in control of the Company. At issuance, the promissory
notes were used to settle certain executives’ and employees’
obligations for 2,883,672 vested and 4,603,833 unvested ISOs that
were exercised and no cash was exchanged. In March 2021, in
connection with the close of the Merger, the Company forgave half
of the respective obligations under the promissory notes for
certain executives and required such noteholders to repay the
remaining balance of $0.3 million under each of their
respective notes. Additional compensation expense of
$0.3 million was recognized in general and administrative
expenses for the three months ended March 31, 2021 for the value of
the loans forgiven. No obligations under the promissory notes for
non-executive noteholders were outstanding as of March 31, 2022 and
December 31, 2021.
Stock Options
Stock option activity for the three months ended March 31,
2022 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Underlying
Outstanding
Options |
|
Weighted-
Average Exercise
Price per Share |
|
Weighted-
Average
Remaining
Contractual
Term (in years) |
|
Aggregate
Intrinsic
Value |
Outstanding—December 31, 2021 |
|
|
24,129,096 |
|
|
$ |
1.01 |
|
|
8.6 |
|
$ |
100,992 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercised |
|
|
(797,380) |
|
|
0.20 |
|
|
|
|
|
Options cancelled |
|
|
(77,753) |
|
|
4.21 |
|
|
|
|
$ |
— |
|
Outstanding—March 31, 2022 |
|
|
23,253,963 |
|
|
$ |
1.03 |
|
|
8.3 |
|
$ |
84,888 |
|
Vested and expected to vest—March 31, 2022 |
|
|
23,253,963 |
|
|
$ |
1.03 |
|
|
8.3 |
|
$ |
84,888 |
|
Exercisable—March 31, 2022 |
|
|
9,954,974 |
|
|
$ |
0.80 |
|
|
8.1 |
|
$ |
37,186 |
|
The following table summarizes information about stock options
outstanding and exercisable at March 31, 2022.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
Options Exercisable |
Exercise
Price |
|
Options
Outstanding |
|
Weighted
Average
Remaining
Contractual
Life (Years) |
|
Weighted
Average
Exercise
Price |
|
Options
Exercisable |
|
Weighted
Average
Exercise
Price |
$ |
0.18 |
|
|
5,037,657 |
|
|
8.3 |
|
$ |
0.18 |
|
|
3,256,438 |
|
|
$ |
0.18 |
|
$ |
0.21 |
|
|
9,300,668 |
|
|
8.5 |
|
$ |
0.21 |
|
|
3,454,922 |
|
|
$ |
0.21 |
|
$ |
1.42 |
|
|
7,524,114 |
|
|
8.5 |
|
$ |
1.42 |
|
|
2,664,790 |
|
|
$ |
1.42 |
|
$ |
1.49 |
|
|
40,581 |
|
|
5.8 |
|
$ |
1.49 |
|
|
40,418 |
|
|
$ |
1.49 |
|
$ |
5.24 |
|
|
705,146 |
|
|
4.0 |
|
$ |
5.24 |
|
|
538,406 |
|
|
$ |
5.24 |
|
$ |
10.26 |
|
|
645,797 |
|
|
9.1 |
|
$ |
10.26 |
|
|
— |
|
|
$ |
— |
|
|
|
23,253,963 |
|
|
|
|
|
|
9,954,974 |
|
|
|
As of March 31, 2022, there was approximately $21.2 million of
unamortized stock-based compensation expense related to unvested
stock options that is expected to be recognized over a weighted
average period of 2.4 years.
Restricted Stock Unit (“RSU”) Awards
A summary of RSU activity is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
Shares |
|
Weighted Average
Grant Date Fair
Value (per share)
|
Unvested – December 31, 2021
|
9,326,572 |
|
|
$ |
7.82 |
|
Granted during the period |
3,983,474 |
|
|
4.25 |
|
Canceled during the period |
(1,559,964) |
|
|
6.44 |
|
Vested during the period |
(828,921) |
|
|
7.46 |
|
Unvested — March 31, 2022
|
10,921,161 |
|
|
$ |
6.75 |
|
Stock compensation expense is recognized on a straight-line basis
over the vesting period of each RSU. As of March 31, 2022,
total compensation expense related to unvested RSUs granted to
employees, but not yet recognized, was $68.1 million, with a
weighted-average remaining vesting period of 3.2
years.
RSUs settle into shares of common stock upon vesting.
Stock-Based compensation expense
Stock-based compensation expense is included in costs and expenses
as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
Cost of revenue |
$ |
217 |
|
|
$ |
118 |
|
Research and development |
3,761 |
|
|
921 |
|
Sales and marketing |
1,524 |
|
|
265 |
|
General and administrative |
3,248 |
|
|
3,952 |
|
Total stock-based compensation |
$ |
8,750 |
|
|
$ |
5,256 |
|
The following table summarizes stock-based compensation expense by
award type (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
RSUs |
$ |
5,901 |
|
|
$ |
313 |
|
Stock options |
2,840 |
|
|
4,937 |
|
RSAs |
9 |
|
|
6 |
|
Total stock-based compensation |
$ |
8,750 |
|
|
$ |
5,256 |
|
Note 10. Net Loss Per Common Share
The following table sets forth the computation of basic and diluted
net loss per common share attributable to common stockholders (in
thousands, except share and per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
Numerator: |
|
|
|
Net loss |
$ |
(32,397) |
|
|
$ |
(20,957) |
|
Denominator: |
|
|
|
Weighted average shares used to compute basic and diluted net loss
per share |
170,906,196 |
|
|
55,688,281 |
|
Net loss per common share—basic and diluted |
$ |
(0.19) |
|
|
$ |
(0.38) |
|
The following outstanding shares of potentially dilutive securities
were excluded from the computation of diluted net loss per share
attributable to common stockholders for the periods presented
because including them would have been antidilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
Options to purchase common stock |
25,577,679 |
|
|
24,626,748 |
|
Public and private common stock warrants |
15,999,900 |
|
|
15,999,996 |
|
Restricted Stock Units |
8,597,445 |
|
|
959,874 |
|
Unvested early exercised common stock options |
1,595,966 |
|
|
3,935,428 |
|
Unvested RSA |
11,645 |
|
|
34,932 |
|
Vested and early exercised options subject to nonrecourse
notes |
— |
|
|
1,761,436 |
|
Total |
51,782,635 |
|
|
47,318,414 |
|
Note 11. Income taxes
The Company’s income tax provision for interim periods is
determined using an estimate of the Company’s annual effective tax
rate, adjusted for discrete items arising in the quarter. The
Company’s effective tax rate differs from the U.S. statutory tax
rate primarily due to valuation allowances on the deferred tax
assets as it is more likely than not that some, or all, of the
Company’s deferred tax assets will not be realized. The Company
continues to maintain a full valuation allowance against its net
deferred tax assets. Due to tax losses and the offsetting valuation
allowance, the income tax provision for the three months ended
March 31, 2022 and 2021 was not material to the Company’s
condensed consolidated financial statements.
Note 12. Revenue
Revenue from sale of lidar sensor kits, which are recognized at a
point in time, was $8.6 million and $6.6 million in three
months ended March 31, 2022 and 2021.
The following table presents total revenues by geographic area
based on the location products were shipped to and services
provided (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
United States |
$ |
2,863 |
|
|
$ |
1,858 |
|
North and South America, excluding United States |
456 |
|
|
366 |
|
Asia and Pacific |
2,356 |
|
|
1,254 |
|
Europe, Middle East and Africa |
2,883 |
|
|
3,133 |
|
Total |
$ |
8,558 |
|
|
$ |
6,611 |
|
Note 13. Related Party Transactions
See Note 5, Debt for details of promissory notes issued by the
Company to certain investors of the Company (or an affiliate
thereof).
See Note 9, Stock-based compensation for details of partial
recourse promissory notes issued by the Company to certain
executives and employees.
Note 14. Subsequent Events
On April 29, 2022, the Company and its subsidiary, Sense, entered
into a loan and security agreement with Hercules Capital, Inc.
(“Hercules”) pursuant to which Hercules agreed to make available to
the Company a secured term loan facility in the amount of up to
$50.0 million, subject to certain terms and conditions.
Advances under the loan and security agreement bear interest at the
rate of interest equal to greater of either (i) (x) the prime rate
as reported in The Wall Street Journal plus (y) 6.15%, and (ii)
9.40%, subject to compliance with financial covenants and other
conditions. The loan and security agreement includes covenants,
limitations, and events of default customary for similar
facilities. The loan and security agreement matures on May 1,
2026.
In accordance with the terms of the loan and security agreement,
$20.0 million was funded by Hercules on the closing date. The
Company may borrow an additional $20.0 million on or before
March 15, 2023, subject satisfying certain conditions. An
additional $10.0 million may be drawn on or before June 15,
2023, subject to satisfying certain conditions relating to the
achievement of trailing twelve month revenue and profit
milestones.
On April 29, 2022, the Company entered into an At-Market-Issuance
Sales Agreement pursuant to which the Company may, subject to the
terms and conditions set forth in the agreement offer and sell,
from time to time, through or to the agents, acting as agent or
principal, shares of the Company’s common stock, par value $0.0001
per share, having an aggregate offering price of up to
$150.0 million.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
The following discussion of the results of operations and financial
condition of Ouster, Inc. (“we,” “us,” “our,” the “Company,”
“Ouster”) should be read in conjunction with the information set
forth in our condensed consolidated financial statements and the
notes thereto included elsewhere in this Form 10-Q, as well as our
audited consolidated financial statements and the “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” included in Ouster’s Annual Report on Form 10-K filed
with the Securities and Exchange Commission (“SEC”) on February 28,
2022. This discussion may contain forward-looking statements based
upon current expectations that involve risks and uncertainties.
Ouster’s actual results may differ materially from those
anticipated in these forward-looking statements as a result of
various factors, including those set forth in the section titled
“Risk Factors” in Ouster’s Annual Report on Form 10-K dated and
filed with the SEC on February 28, 2022.
On December 21, 2020, Ouster Technologies, Inc. (“OTI”, prior to
the Merger, named Ouster, Inc.) entered into an Agreement and Plan
of Merger (the “Merger Agreement”) with Colonnade Acquisition
Corp., a Cayman Islands exempted company (“CLA”), and Beam Merger
Sub, Inc. (“Merger Sub”), a Delaware corporation and subsidiary of
CLA. OTI’s and CLA’s board of directors unanimously approved OTI’s
entry into the Merger Agreement, and on March 11, 2021, the
transactions contemplated by the Merger Agreement were consummated
(all such transactions, the “Merger”), as further described
below.
Unless the context otherwise requires, references in this
subsection to “we”, “our” and “the Company” refer to the business
and operations of OTI (formerly known as Ouster, Inc.) and its
consolidated subsidiaries prior to the Merger and to Ouster, Inc.
(formerly known as Colonnade Acquisition Corp.) and its
consolidated subsidiaries following the consummation of the
Merger.
Overview
We are a leading provider of high-resolution digital lidar sensors
that offer advanced 3D vision to machinery, vehicles, robots, and
fixed infrastructure assets, allowing each to understand and
visualize the surrounding world and ultimately enabling safe
operation and autonomy. We design and manufacture digital lidar
sensors that we believe are the highest-performing, lowest-cost
lidar solutions available today across each of our four target
markets: industrial automation; smart infrastructure; robotics; and
automotive. We shipped sensors to over 650 customers in the twelve
months ended March 31, 2022.
Our digital lidar sensors leverage a simplified architecture based
on two semiconductor chips and are backed by a suite of
patent-protected technology. We have invested heavily in patents
since our inception, pursuing comprehensive coverage of invention
families and use cases, with broad international coverage. We
believe that our extensive patent coverage creates material
barriers to entry for anyone aiming to compete in the digital lidar
space.
Our product offering today includes our OS scanning product line
and our DF solid-state product line. With our unique digital lidar
technology, we offer numerous customization options across our
products, all enabled by flexible technology and embedded software.
Today we offer short, medium, and long-range lidar products at
varying price points and with tailored capabilities to meet the
different needs of our diverse customer base.
We believe the simplicity of our digital lidar design gives us a
meaningful advantage in costs related to manufacturing, supply
chain and production yields. The same digital lidar components
underpin our entire product portfolio which drives economies of
scale in our supply chains. With virtually unlimited
software-defined products driving low-cost customization, we are
able to increase stock keeping units (“SKUs”) for industry-specific
applications, expanding our product offering with minimal
manufacturing or inventory changes. We currently offer many
different software-defined product SKUs, all based on this common
architecture and shared core componentry. Additionally, we are
successfully expanding our manufacturing capacity by outsourcing to
our manufacturing partner, Benchmark Electronics, Inc.
(“Benchmark”). Benchmark manufactures our products at its facility
in Thailand, which we expect will reduce our product costs and
allow us to rapidly scale production to meet our anticipated
product demand. Based on cost quotes for our products in mass
production, we believe our manufacturing costs to be lower than
certain of our competitors, and we expect our manufacturing costs
per unit to decrease further with higher volumes.
We have won and are actively negotiating several multi-year sales
contracts, including certain Strategic Customer Agreements
(“SCAs”), which establish a multi-year purchase and supply
framework for Ouster and the customer, and include details about
customer programs and applications where the customer intends to
use Ouster products. SCAs also include multi-year non-binding
customer forecasts (typically of three to five years in length)
giving Ouster visibility to the customer's long-term purchasing
requirements, mutually agreed upon pricing over the duration of the
agreement, and, in certain cases, include multi-year binding
purchase commitments.
We founded Ouster in 2015 with the invention of our
high-performance digital lidar. Since then, we have grown to
approximately 280 employees serving over 650 customers globally in
the twelve months ended March 31, 2022. To continue to grow
our business in the coming years, we have expanded and plan to
continue to expand our sales and marketing efforts and our software
development capabilities, and to accelerate sensor development
efforts. We are headquartered in San Francisco, CA.
Merger Agreement with Colonnade Acquisition Corp. and Beam Merger
Sub, Inc.
On December 21, 2020, OTI entered into the Merger Agreement with
CLA, and Merger Sub, a subsidiary of CLA. OTI’s and CLA’s board of
directors unanimously approved OTI’s entry into the Merger
Agreement, and on March 11, 2021, the transactions contemplated by
the Merger Agreement were consummated. Pursuant to the terms of the
Merger Agreement, (i) CLA domesticated as a corporation
incorporated under the laws of the State of Delaware (the
“Domestication”) and changed its name to “Ouster, Inc.” (with CLA
after such domestication and the other transactions pursuant to the
Merger Agreement being referred to as the “Company”) and (ii)
Merger Sub merged with and into OTI (the “Merger”), with OTI
surviving the Merger.
As a result of and upon the effective time of the Domestication,
among other things, (1) each of the then issued and outstanding
5,000,000 CLA Class B ordinary shares, par value $0.0001 per share,
of CLA (the “CLA Class B ordinary shares”) converted automatically,
on a one-for-one basis, into a CLA Class A ordinary share (as
defined below), (2) immediately following the conversion described
in clause (1), each of the then issued and outstanding 25,000,000
Class A ordinary shares, par value $0.0001 per share, of CLA (the
“CLA Class A ordinary shares”), converted automatically, on a
one-for-one basis, into a share of common stock, par value $0.0001
per share, of Ouster (the “Ouster common stock”), (3) each of the
then issued and outstanding 10,000,000 redeemable warrants of CLA
(the “CLA warrants”) converted automatically into a redeemable
warrant to purchase one share of Ouster common stock (the “Public
warrants”) pursuant to the Warrant Agreement, dated August 20, 2020
(the “Warrant Agreement”), between CLA and Continental Stock
Transfer & Trust Company (“Continental”), as warrant agent, and
(4) each of the then issued and outstanding units of CLA that had
not been previously separated into the underlying CLA Class A
ordinary shares and underlying CLA warrants upon the request of the
holder thereof (the “CLA units”), were cancelled and entitled the
holder thereof to one share of Ouster common stock and one-half of
one Public warrant, and (5) each of the then issued and outstanding
6,000,000 private placement warrants of CLA (the “Private Placement
warrants”) converted automatically into a Public warrant pursuant
to the Warrant Agreement. No fractional Public warrants were issued
upon separation of the CLA units.
Immediately prior to the effective time of the Merger, (1) each
share of OTI’s Series B Preferred Stock, par value $0.00001 per
share (the “OTI Preferred Stock”), converted into one share of
common stock, par value $0.00001 per share, of OTI (the “OTI common
stock” and, together with OTI Preferred Stock, the “OTI Capital
Stock”) (such conversion, the “OTI Preferred Conversion”) and (2)
all of the outstanding warrants to purchase shares of OTI Capital
Stock were exercised in full or terminated in accordance with their
respective terms (the “OTI Warrant Settlement”).
As a result of and upon the closing of the Merger, among other
things, all shares of OTI Capital Stock (after giving effect to the
OTI Warrant Settlement) outstanding immediately prior to the
closing of the Merger together with shares of OTI common stock
reserved in respect of options to purchase shares of OTI common
stock and restricted shares of OTI common stock (together, the “OTI
Awards”) outstanding immediately prior to the closing of the Merger
that were converted into awards based on Ouster common stock, were
cancelled in exchange for the right to receive, or the reservation
of, an aggregate of $1.5 billion of shares of Ouster common stock
(at a deemed value of $10.00 per share), which, in the case of OTI
Awards, were shares underlying awards based on Ouster common stock,
representing a fully-diluted pre-transaction shares. Upon the
closing of the Merger, the Company received gross proceeds of
$299.9 million from the Merger and private offering, offset by
$8.5 million of pre-merger costs relating to CLA and
transaction costs of $26.6 million.
Sense Acquisition
On October 22, 2021, we completed the acquisition of Sense
Photonics, Inc. (“Sense”). Under the terms of the merger agreement,
we acquired 100% of Sense and all of its property for approximately
10 million shares of Ouster common stock or approximately $63.0
million in equity value based on the closing price of $6.55 per
share as of the day the transaction closed on October 22, 2021,
inclusive of 0.8 million shares underlying assumed options, after
closing adjustments. This acquisition is expected to help Ouster
expand its presence in the automotive vertical by executing on our
hiring goals and product roadmap on a faster timeline.
COVID-19 Impact
Beginning in 2020, the worldwide spread of the pandemic caused by
the novel coronavirus (“COVID-19”), including its variants, and the
measures intended to contain the spread of COVID-19, have resulted
in a global slowdown of economic activity and caused disruptions to
our business.
For example, our suppliers are located worldwide, and some of our
key suppliers have been affected by the pandemic resulting in
supply chain disruptions. We have experienced and continue to
experience some unfavorable purchase price variance and situational
expedite fees in order to meet production and delivery timelines.
While we may see additional or new pressures on our supply chain
both related and unrelated to the pandemic, we are actively taking
steps to mitigate the impact of the materials shortages on our
business.
At times during the pandemic, some customers have delayed orders
and production schedules due to COVID-19. The pandemic continues to
evolve, and the full extent to which the COVID-19 pandemic will
directly or indirectly impact our business, results of operations
and financial condition, including sales, expenses, reserves and
allowances, manufacturing, research and development costs and
personnel-related costs, will depend on future developments that
are highly uncertain, including new information that may emerge
concerning COVID-19, the impact of new variants of the disease and
the actions taken to contain, prevent or treat COVID-19, rate and
success of vaccination efforts, vaccination reticence, any
resurgence of the pandemic in areas where we, Benchmark or our
suppliers operate, and the economic impact on local, regional,
national and international customers and markets.
Going forward, the situation remains uncertain, rapidly changing
and hard to predict, and the COVID-19 pandemic may have a material
negative impact on our future results.
Factors Affecting Our Performance
Supply Chain Continuity.
Beginning in 2021, a surge in demand for electronics containing
semiconductor chips and stockpiling of chips by certain companies
created disruptions in the supply chain, which has resulted in a
global chip shortage impacting our industry. Some chip
manufacturers are estimating that this supply shortage may continue
through mid-2023. These chip manufacturers are working to increase
capacity in the future, and we are managing our inventory and
working closely with our regular suppliers and customers to
minimize the potential impacts of any supply shortages including by
securing additional inventory. While we do not expect the shortage
to have a material near-term impact on our ability to meet existing
demand for our current products, the shortage adversely impacted
our gross margins for the year ended December 31, 2021 and the
three months ended March 31, 2022 and may continue to do so. We
anticipate fluctuation in our cost of goods sold over the next
12-18 months as a result of ongoing supply chain constraints. These
constraints have caused and may in the future cause us to implement
certain temporary price surcharges. Over time, we expect our
overall average selling prices to decline as our volume increases.
If our mitigating efforts are not successful or the shortage
continues or worsens in ways we did not anticipate, our ability to
supply or improve our current products as well as our development
and rollout of future products could also be adversely
affected.
Commercialization of Lidar Applications.
We believe that lidar is approaching its inflection point of
adoption across our target end market applications, and that we are
well-positioned to capitalize on this market adoption. However, as
our customers continue research and development projects to
commercialize semi-autonomous solutions that rely on lidar
technology, it is difficult to estimate the timing of ultimate end
market and customer adoption. As a result, we expect that our
results of operations, including revenue and gross margins, will
fluctuate on a quarterly and annual basis for the foreseeable
future. As the market for lidar solutions matures and more
customers reach a commercialization phase with solutions that rely
on our technology, the fluctuations in our operating results may
become less pronounced. Nonetheless, our revenue may not grow as we
expect unless and until more customers commercialize their products
and lidar technology becomes more prevalent across our target end
markets.
Number of Customers in Production.
For certain strategic customers and markets, our products must be
integrated into a broader platform, which then must be tested,
validated, and achieve system-level performance and reliability
thresholds that enable commercial production and sales. The time
necessary to reach commercial production varies from six months to
seven years, based on the market and application. For example, the
production cycle in the automotive market tends to be substantially
longer than in our other target markets, including industrial
automation, smart infrastructure and robotics. It is critical to
our future success in each of our target end markets that our
customers reach commercial production and sales and that they
select our products in their commercial production applications.
Because the timelines to reach production vary significantly and
the revenue generated by each customer in connection with
commercial production and sales is unpredictable, it is difficult
for us to reliably predict our financial performance.
Customer’s Sales Volumes.
Our customer base is diversified and we will continue to penetrate
into diverse end markets to increase our sales volumes. Ultimately
widespread adoption of our customers’ products that incorporate our
lidar solutions will depend on many factors, including the size of
our customers’ end markets, end market penetration of our
customer’s products that incorporate our digital lidar solutions,
our end customers’ ability to sell their products, and the
financial stability and reputation of the customers. We believe our
sales volume by customer depends on the end market demand for our
customers’ products that incorporate our digital lidar solutions as
well as our ability to grow our sales force.
Average Selling Prices (“ASPs”), Product Costs and Margins.
Our product costs and gross margins depend largely on the volumes
of sensors sold and the number and variety of solutions we provide
to our customers. We expect that our selling prices will vary by
target end market and application due to market-specific supply and
demand dynamics. We expect to continue to experience some downward
pressure on margins from signing anticipated large multi-year
agreements (including our SCAs) in the near term with multi-year
negotiated pricing, as well as supply chain constraints discussed
above. We expect these customer-specific selling price fluctuations
combined with our volume-driven product costs may drive
fluctuations in revenue and gross margins on a quarterly basis.
However, notwithstanding any short-term price surcharge on our
products, we expect that over time our volume-driven product costs
will lead to gross margin improvement as our sales volume
increases.
Competition.
Lidar is an emerging market, and there are competitors for the
growing market. Competitors may offer lidar products at lower
prices than ours, including pricing that may be below their cost,
or may offer superior performing lidar products. These companies
also compete with us indirectly by attempting to solve some of the
same challenges with different technology. Established competitors
in the market for lidar sensors have significantly greater
resources and more experience than we do. These competitors have
commercialized lidar technology that has achieved market adoption,
strong brand recognition and may continue to improve in both
anticipated and unanticipated ways. They may also enter, and have
entered, into commercial relationships with key customers and
potential customers and have built relationships and dependencies
between themselves and those key customers and potential customers.
This has created downward pressure on our ASPs, particularly in the
Asia and Pacific region. We expect this pressure to continue to
push our ASPs lower in the coming years. However, we believe that
because of our complementary metal-oxide-semiconductor (“CMOS”),
digital lidar technology, we are in the position to scale more
rapidly than our analog competitors and leverage our scale to
deliver positive gross margins.
Continued Investment and Innovation.
We believe that we are a leading digital lidar provider. Our
financial performance is significantly dependent on our ability to
maintain this leading position which is further dependent on the
investments we make in research and development. We believe it is
essential that we continue to identify and respond to rapidly
evolving customer requirements, including successfully realizing
our product roadmap. If we fail to continue our innovation, our
market position and revenue may be adversely affected, and our
investments in that area will not be recovered.
Market Trends and Uncertainties.
We anticipate robust demand for our digital lidar solution. We
estimate a multibillion dollar total addressable market (“TAM”) for
our solutions in the near future. We define our TAM as automation
applications in the industrial, smart infrastructure, robotics and
automotive end markets where we actively engage and maintain
customer relationships. Each of our target markets is potentially a
significant global opportunity, and these markets have historically
been underserved by limited or inferior technology or not served at
all. We believe we are well positioned in our market as a leading
provider of high-resolution digital lidar sensors.
Although increasing adoption of semi-autonomous solutions that rely
on lidar technology may generate higher demand, we may not be able
to take advantage of demand if we are unable to anticipate
regulatory changes and adapt quickly enough to meet such new
regulatory standards or requirements applicable to us or to our
customers’ products in which our digital lidar sensors are used.
Market acceptance of semi-autonomous solutions and active safety
technology depend upon many factors, including cost, performance,
safety performance, regulatory requirements and international taxes
or tariffs related to such technologies. These factors may impact
the ultimate market acceptance of our lidar
technology.
International Expansion.
We view international expansion as an important element of our
strategy to increase revenue and achieve profitability. We continue
to position ourselves in geographic markets that we expect to serve
as important sources of future growth. We have an existing presence
in three regions: North and South America; Asia and Pacific; and
Europe, Middle East and Africa. We intend to expand our presence in
these regions over time including through distribution
partnerships. Expanded global reach will require continued
investment and may expose us to additional foreign currency risk,
international taxes and tariffs, legal obligations and additional
operational costs, risks and challenges that may impact our ability
to meet our projected sales volumes, revenue and gross
margins.
Components of Results of Operations
Revenue
The majority of our revenue comes from the sale of our digital
lidar sensors and accessories both directly to end users and
through distributors both domestically and internationally. We
recognize revenue from product sales when the performance
obligation of transferring control of the product to the customer
has been met, generally when the product is shipped. We also
recognize revenue by performing services related to product
development and validation, and shipping; however, we do not expect
product development and validation and license and services to be
material components of revenue, cost of revenue or gross margin in
the foreseeable future. Performance obligations related to services
are generally recognized over time, based on cost-to-cost input
basis or straight-line over time. Amounts billed to customers
related to shipping and handling are classified as product revenue,
and we have elected to recognize the cost of shipping activities
that occur after control has transferred to the customer as a
fulfillment cost rather than a separate performance obligation. All
related costs are accrued and recognized within cost of revenue
when the related revenue is recognized.
Most of our customers are currently in the evaluation or early
R&D stage with our products. Currently, our product revenue
consists of both customers ordering small volumes of our products
that are in an evaluation phase and customers that order larger
volumes of our products and have more predictable long-term
production schedules. However, we are still at the very beginning
of the lidar adoption curve, and some customers are still learning
their ramp rates which can impact the timing of purchase orders
quarter to quarter. As we grow our business we expect to improve
predictability into our customers’ needs and timelines, and expect
the timing of orders will have a less notable impact on our
quarterly results. Over the coming years, as more of our customers
move into their respective production phases, we expect the
majority of our product revenue to shift to larger volume orders
based on predictable production schedules.
Cost of Revenue
Cost of revenue consists of the manufacturing cost of our digital
lidar sensors, which primarily consists of sensor components,
personnel-related costs directly associated with our manufacturing
organization, and amounts paid to our third-party contract
manufacturer and vendors. Our cost of revenue also includes
depreciation of manufacturing equipment, an allocated portion of
overhead, facility and IT costs, stock-based compensation for
manufacturing personnel, reserves for estimated warranty expenses,
excess and obsolete inventory and shipping costs.
Gross Profit and Gross Margin
Our gross profit equals total revenues less our total cost of
revenues, and our gross margin is our gross profit expressed as a
percentage of total revenue. Subject to quarterly fluctuations and
volatility, we expect unit costs to improve as we manufacture
higher unit volumes of sensors and a greater portion of our sensors
are produced by our contract manufacturer in Thailand.
Operating Expenses
Research and Development Expenses
Research and development (“R&D”) activities are primarily
conducted at our San Francisco based headquarters and our
additional R&D facility in Edinburgh, Scotland and consist of
the following activities:
•Design,
prototyping, and testing of proprietary electrical, optical, and
mechanical subsystems for our digital lidar products;
•Robust
testing for industrial and autonomous vehicle safety
certifications;
•Development
of new products and enhancements to existing products in response
to customer requirements including firmware development and
software development of lidar integration products;
•Custom
system-on-a-chip (“SoC”) design for Ouster’s digital lidar
products; and
•Development
of custom manufacturing equipment.
R&D expenses consist of personnel-related expenses, including
salaries, benefits, and stock-based compensation, for all personnel
directly involved in R&D activities, third-party engineering
and contractor costs, and prototype expenses.
R&D costs are expensed as they are incurred. Our investment in
R&D will continue to grow as we invest in new lidar technology
and related software. Our absolute amount of R&D expense will
grow over time; however, we expect R&D as a percentage of
revenue to decrease annually as our business grows.
Sales and Marketing Expenses
Our business development, customer support and marketing teams are
located in offices worldwide. Selling and marketing expenses
consist of personnel-related expenses, including salaries,
benefits, and stock-based compensation, for all personnel directly
involved in business development, customer support, and marketing
activities, and marketing expenses including trade shows,
advertising, and demonstration equipment. Our investment in sales
and marketing will continue to grow as we continue to expand our
sales team globally, and our absolute amount of sales and marketing
expenses will grow over time. We expect sales and marketing spend
as a percentage of revenue to decrease over time as our business
grows.
General and Administrative Expenses
General and administrative expenses consist of personnel-related
expenses, including salaries, benefits, and stock-based
compensation, of our executives and members of the board of
directors, finance, human resource, IT, and legal departments as
well as fees related to legal fees, patent prosecution, accounting,
finance and professional services as well as insurance, and bank
fees. Our absolute amount of general and administrative expense
will grow over time; however, we expect the general and
administrative spend as a percentage of revenue to decrease
annually as our business grows. Near term increases in general and
administrative expenses are expected to be related to hiring more
personnel and consultants to support our growing international
expansion and compliance with the applicable provisions of the
Sarbanes-Oxley Act (“SOX”) and other U.S. Securities and Exchange
Commission (“SEC”) rules and regulations.
Stock-Based Compensation
We measure and recognize stock-based compensation expense for
stock-based awards over the requisite service periods based on the
estimated grant date fair value using the Black-Scholes-Merton
option pricing model.
Interest Income, Interest Expense, and Other Income (Expense),
Net
Interest income consists primarily of income earned on our cash and
cash equivalents. These amounts will vary based on our cash and
cash equivalents balances and market rates. Interest expense
consists primarily of interest on our debt and convertible notes
and amortization of debt issuance costs and discount. Other income
(expense), net consists primarily of realized and unrealized gains
and losses on foreign currency transactions and balances, the
change in fair value of financial instruments, including warrants
issued in connection with a debt agreement, and Private Placement
warrants acquired as part of the Merger.
Income Taxes
Our income tax provision consists of federal, state and foreign
current and deferred income taxes. Our income tax provision for
interim periods is determined using an estimate of our annual
effective tax rate, adjusted for discrete items arising in the
quarter. Our effective tax rate differs from the U.S. statutory tax
rate primarily due to valuation allowances on its deferred tax
assets as it is more likely than not that some, or all, of our
deferred tax assets will not be realized. We continue to maintain a
full valuation allowance against its net deferred tax assets.
Income tax provision for the three months ended March 31, 2022 and
2021, respectively, was not material to the Company’s condensed
consolidated financial statements.
Results of Operations:
The following table sets forth our condensed consolidated results
of operations data for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
|
(dollars in thousands) |
|
|
|
|
Product revenue |
$ |
8,558 |
|
|
$ |
6,611 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue
(1)
|
5,967 |
|
|
4,868 |
|
|
|
|
|
|
|
|
|
Gross profit |
2,591 |
|
|
1,743 |
|
Operating expenses
(1):
|
|
|
|
Research and development |
15,906 |
|
|
4,712 |
|
Sales and marketing |
7,090 |
|
|
3,426 |
|
General and administrative |
13,783 |
|
|
9,907 |
|
Total operating expenses |
36,779 |
|
|
18,045 |
|
Loss from operations |
(34,188) |
|
|
(16,302) |
|
Other (expense) income: |
|
|
|
Interest income |
154 |
|
|
1 |
|
Interest expense |
— |
|
|
(504) |
|
Other income (expense), net |
1,684 |
|
|
(4,152) |
|
Total other expense, net |
1,838 |
|
|
(4,655) |
|
Loss before income taxes |
(32,350) |
|
|
(20,957) |
|
Provision for income tax expense |
47 |
|
|
— |
|
Net loss |
$ |
(32,397) |
|
|
$ |
(20,957) |
|
The following table sets forth the components of our condensed
consolidated statements of operations and comprehensive loss data
as a percentage of revenue for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
|
(% of total revenue) |
|
|
|
|
Product revenue |
100 |
% |
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue
(1)
|
70 |
|
|
74 |
|
|
|
|
|
|
|
|
|
Gross profit |
30 |
|
|
26 |
|
Operating expenses
(1):
|
|
|
|
Research and development |
186 |
|
|
71 |
|
Sales and marketing |
83 |
|
|
52 |
|
General and administrative |
161 |
|
|
150 |
|
Total operating expenses |
430 |
|
|
273 |
|
Loss from operations |
(400) |
|
|
(247) |
|
Other (expense) income: |
|
|
|
Interest income |
2 |
|
|
— |
|
Interest expense |
— |
|
|
(8) |
|
Other income (expense), net |
20 |
|
|
(63) |
|
Total other expense, net |
22 |
|
|
(71) |
|
Loss before income taxes |
(378) |
|
|
(318) |
|
Provision for income tax expense |
1 |
|
|
— |
|
Net loss |
(379) |
% |
|
(318) |
% |
(1)Includes
stock-based compensation expense as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
Cost of revenue |
$ |
217 |
|
|
$ |
118 |
|
Research and development |
3,761 |
|
|
921 |
|
Sales and marketing |
1,524 |
|
|
265 |
|
General and administrative |
3,248 |
|
|
3,952 |
|
Total stock-based compensation |
$ |
8,750 |
|
|
$ |
5,256 |
|
Comparison of the three months ended March 31, 2022 and
2021
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
Change |
|
Change |
|
2022 |
|
2021 |
|
$ |
|
% |
|
(dollars in thousands) |
|
|
|
|
|
|
|
|
Product revenue |
$ |
8,558 |
|
|
$ |
6,611 |
|
|
$ |
1,947 |
|
|
29 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by geographic location: |
|
|
|
|
|
|
|
United States |
$ |
2,863 |
|
|
$ |
1,858 |
|
|
$ |
1,005 |
|
|
54 |
% |
North and South America, excluding United States |
456 |
|
|
366 |
|
|
90 |
|
|
25 |
|
Asia and Pacific |
2,356 |
|
|
1,254 |
|
|
1,102 |
|
|
88 |
|
Europe, Middle East and Africa |
2,883 |
|
|
3,133 |
|
|
(250) |
|
|
(8) |
|
Total |
$ |
8,558 |
|
|
$ |
6,611 |
|
|
$ |
1,947 |
|
|
29 |
% |
Product Revenue
Product revenue increased by $1.9 million, or 29%, to $8.6 million
for the three months ended March 31, 2022 from $6.6 million for the
comparable period in the prior year. The increase in product
revenue was driven by an increase in volume of 58%, which we
attribute primarily to the expansion of our sales team into new
geographic regions and the increase of high volume, long-term deals
as some of our customers begin to move into a production stage with
their autonomous products. Our average selling price declined by
20% as we moved towards negotiated customer pricing with customers
reaching the production stage with their autonomous products and we
expect reductions in the cost of goods sold as we grow our
volumes.
Geographic Locations
Revenue increased across the geographic regions of United States;
North and South America, excluding United States; and Asia and
Pacific; by $1.0 million, $0.1 million, and $1.1 million,
respectively. The revenue increases in those geographic regions
were a result of recent sales expansion. Revenue decreased in
Europe, Middle East and Africa due to a large one time contract
which was fulfilled during the three months ended March 31, 2021
and represented 57% of the revenue from Europe, Middle East and
Africa in the first quarter of 2021.
Cost of Product Revenue and Gross Margin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
Change |
|
Change |
|
2022 |
|
2021 |
|
$ |
|
% |
|
(dollars in thousands) |
|
|
|
|
|
|
|
|
Cost of product revenue |
$ |
5,967 |
|
|
$ |
4,868 |
|
|
$ |
1,099 |
|
|
23 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Product Revenue and Gross Margin
Cost of product revenue increased by $1.1 million, or 23%, to $6.0
million for the three months ended March 31, 2022 from $4.9 million
for the comparable period in the prior year and cost per unit
decreased by 23%. The increase in cost of product revenue was
primarily due to an increase of $0.5 million purchase price
variance due to the supply chain shortage, increases related to
volume of $1.0 million in material costs, $0.1 million in freight
costs and $1.1 million in manufacturing overhead costs and an
increase of $0.1 million in cost per unit in freight. The increases
were partially offset by a decrease of $1.7 million in per unit
costs of materials, labor and overhead and other costs related to
product revenue.
Gross margin increased from 26% for the three months ended March
31, 2021 to 30% for the three months ended March 31, 2022. The
increase in product gross margin is due to the 23% decrease in cost
per unit partially offset by the 20% decrease in average selling
price.
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
Change |
|
Change |
|
2022 |
|
2021 |
|
$ |
|
% |
|
(dollars in thousands) |
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
$ |
15,906 |
|
|
$ |
4,712 |
|
|
$ |
11,194 |
|
|
238 |
% |
Sales and marketing |
7,090 |
|
|
3,426 |
|
|
3,664 |
|
|
107 |
|
General and administrative |
13,783 |
|
|
9,907 |
|
|
3,876 |
|
|
39 |
|
Total operating expenses: |
$ |
36,779 |
|
|
$ |
18,045 |
|
|
$ |
18,734 |
|
|
104 |
% |
Research and Development
Research and development expenses increased by $11.2 million, or
238%, to $15.9 million for the three months ended March 31, 2022
from $4.7 million for the comparable period in the prior year. The
increase was primarily attributable to a $4.6 million increase in
payroll and benefits related costs, a $2.9 million increase in
stock-based compensation expense, a $2.4 million increase in
contractor, prototype, and equipment costs related to product
development, a $0.7 million in depreciation and amortization
expense, and a $0.6 million increase in other materials and
supplies, facilities, professional fees and other miscellaneous
costs attributable to research and development
functions.
Sales and Marketing
Sales and marketing expenses increased by $3.7 million, or 107%, to
$7.1 million for the three months ended March 31, 2022 from $3.4
million for the comparable period in the prior year. The increase
was primarily attributable to an increase of $2.1 million in
payroll and personnel-related costs and $1.3 million in stock-based
compensation expense driven by the addition of sales personnel in
all our global regions, as well as a $0.3 million increase in other
expenses associated with our marketing and business development
programs.
General and Administrative
General and administrative expenses increased by $3.9 million, or
39%, to $13.8 million for the three months ended March 31, 2022
from $9.9 million for the comparable period in the prior year. The
increase was primarily due to an increase of $1.4 million in
payroll and personnel-related costs, an increase of $1.3 million in
insurance premiums, an increase of $0.6 million in depreciation
expenses, an increase of $0.5 million in professional services
fees, and an increase of $0.8 million in office, facility and other
expenses, partially offset by a decrease of $0.7 million in stock
based compensation expenses.
Interest Income, Interest Expense and Other Income (Expense),
Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
Change |
|
Change |
|
2022 |
|
2021 |
|
$ |
|
% |
|
(dollars in thousands) |
Interest income |
$ |
154 |
|
|
$ |
1 |
|
|
$ |
153 |
|
|
* |
Interest expense |
— |
|
|
(504) |
|
|
504 |
|
|
(100) |
|
Other income (expense), net |
1,684 |
|
|
(4,152) |
|
|
5,836 |
|
|
(141) |
|
*Not meaningful
Interest income was $0.2 million for the three months ended March
31, 2022 compared to $0.001 million for the comparable period in
the prior year. This increase in interest income was primarily
related to an increase in our cash and cash equivalent
balances.
Interest expense was nil for the three months ended March 31, 2022
compared to $0.5 million for the comparable period in the prior
year. The decrease was primarily because we recorded interest
expense on our debt and convertible notes and amortization of debt
issuance costs and discount for the comparable period in the prior
year.
Other income (expense), net was $1.7 million for the three months
ended March 31, 2022 compared to $4.2 million for the comparable
period in the prior year. During the three months ended March 31,
2022, we recorded a gain of $1.7 million for the fair value change
of Private Placement warrant liability which was offset by
$0.1 million gain from disposal of property and equipment.
During the three months ended March 31, 2021, we recorded a loss of
$8.8 million for the fair value change of redeemable convertible
preferred stock warrant liability, partially offset by a gain of
$4.7 million for the fair value change of Private Placement warrant
liability which was recorded as other income.
Income Taxes
We were subject to income tax in the United States, California, and
miscellaneous foreign jurisdictions for the three months ended
March 31, 2022 and 2021. Our income tax expense for three months
ended March 31, 2022 and 2021 was not material to the Company’s
condensed consolidated financial statements.
Liquidity and Capital Resources
Sources of Liquidity
Our primary requirements for liquidity and capital are working
capital, inventory management, capital expenditures, public company
costs and general corporate needs. We expect these needs to
continue as we develop and grow our business. Prior to the Merger,
we primarily funded our operations from the net proceeds from sales
of our preferred convertible stock and convertible notes, borrowing
under our loan and security agreement with Runway Growth Credit
Fund, Inc. and product revenue. Upon closing of the Merger, we
received gross proceeds of $299.9 million from the Merger and
private offering, offset by $8.5 million of pre-merger costs
relating to CLA and transactions costs of $26.6
million.
On April 29, 2022, we entered into an open market sale agreement
with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and
Oppenheimer & Co. Inc., pursuant to which we may offer and sell
shares of our common stock with an aggregate offering price of up
to $150.0 million under an “at the market” offering program (the
“ATM Offering”). Subject to the terms and conditions of the
agreement, we may sell the shares in amounts and at times to be
determined by us but we have no obligation to sell any of the
shares. Actual sales, if any, will depend on a variety of factors
to be determined by us from time to time, including, among other
things, market conditions, the trading price of our common stock,
capital needs and determinations by us of the appropriate sources
of its funding. We currently intend to use the net proceeds from
any sale of shares pursuant to the ATM Offering for working capital
and general corporate purposes.
On April 29, 2022, we entered into a loan and security agreement
(the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”).
The Loan Agreement provides us with the term loan of up to $50.0
million, subject to terms and conditions. $20.0 million has been
drawn to date under the Loan Agreement, and can be used for general
working capital purposes. For additional information, see “Debt
Arrangements” below.
Our principal sources of liquidity are expected to be our cash and
cash equivalents, cash generated from product revenues, sales of
common stock under our at-the market equity offering program and
our loan agreement executed with Hercules.
As of March 31, 2022, we had an accumulated deficit of $335.8
million and cash and cash equivalents of $160.8 million. We have
experienced recurring losses from operations, and negative cash
flows from operations, and we expect to continue operating at a
loss and to have negative cash flows from operations for the
foreseeable future. We believe our cash and cash equivalents on
hand, together with cash we expect to generate from future
operations, will be sufficient to meet our working capital and
capital expenditure requirements for a period of at least twelve
months from the date of this Quarterly Report on Form 10-Q.
However, because we are in the growth stage of our business and
operate in an emerging field of technology, we expect to continue
to invest in research and development and expand our sales and
marketing teams worldwide. We are likely to require additional
capital to respond to technological advancements, competitive
dynamics or technologies, customer demands, business opportunities,
challenges, acquisitions or unforeseen circumstances and in either
the short-term or long-term may determine to engage in equity or
debt financings or enter into credit facilities for other reasons.
If we are unable to obtain adequate financing or financing on terms
satisfactory to us, when we require it, our ability to continue to
grow or support our business and to respond to business challenges
could be significantly limited. In particular, the widespread
COVID-19 pandemic, including variants, has resulted in, and may
continue to result in, significant disruption of global financial
markets, reducing our ability to access capital. If we are unable
to raise additional funds when or on the terms desired, our
business, financial condition and results of operations could be
adversely affected.
PIPE Investment
On December 21, 2020, concurrently with the execution of the Merger
Agreement, CLA entered into subscription agreements with certain
institutional and accredited investors (collectively, the “PIPE
Investors”), pursuant to which the PIPE Investors agreed to
purchase, in the aggregate, 10,000,000 shares of Ouster common
stock at $10.00 per share for an aggregate commitment amount of
$100,000,000 (the “PIPE Investment”), a portion of which was funded
by certain affiliates of Colonnade Sponsor LLC, CLA’s sponsor (the
“Sponsor”). The PIPE Investment was consummated substantially
concurrently with the closing of the Merger.
Debt Arrangements
On November 27, 2018, we entered into a Loan and Security Agreement
with Runway Growth Credit Fund, Inc. (“Runway Loan and Security
Agreement”) and borrowed $10.0 million per the terms of that
agreement with a loan maturity date of November 15, 2021. The loan
carried an interest rate equal to LIBOR plus 8.50%. We repaid $3.0
million of the loan in August 2020. On March 26, 2021 we terminated
the Runway Loan and Security Agreement and repaid the $7.0 million
principal amount outstanding as well as interest and fees amounting
to $0.4 million. We incurred no prepayment fees in connection with
the termination and all liens and security interests securing the
loan made pursuant to the Runway Loan and Security Agreement were
released upon termination. As of March 31, 2022 and
December 31, 2021, the outstanding principal balance of the
loan was nil.
As described above, on April 29, 2022, we entered into the Loan
Agreement with Hercules. The Loan Agreement provides us with a term
loan facility of up to $50.0 million, subject to terms and
conditions (the “Term Loan Facility”). $20.0 million has been drawn
to date under the Loan Agreement, and can be used for general
working capital purposes. We may borrow an additional $20.0 million
on or before March 15, 2023, subject satisfying certain conditions.
An additional $10.0 million may be drawn on or before June 15,
2023, subject to satisfying certain conditions relating to the
achievement of trailing twelve month revenue and profit
milestones.
Advances under the Term Loan Facility bear interest at the rate of
interest equal to greater of either (i) (x) the prime rate as
reported in The Wall Street Journal plus (y) 6.15%, and (ii) 9.40%,
subject to compliance with financial covenants and other
conditions. The Loan Agreement includes covenants, limitations, and
events of default customary for similar facilities. The Loan
Agreement matures on May 1, 2026.
Interest on amounts borrowed under the Loan Agreement is payable on
a monthly basis until June 1, 2025. After June 1, 2025, payments
consist of equal monthly installments of principal and interest
payable until the secured obligations are repaid in full. However,
if the Company achieves certain equity proceed, revenue or profit
targets for the twelve-month period ending December 31, 2023, then
the interest-only payments will continue and the Company will be
obligated to repay the aggregate principal amount on May 1, 2026.
The entire principal balance and all accrued but unpaid interest
hereunder, shall be due and payable on May 1, 2026. On the earliest
to occur of May 1, 2026, the date on which the obligations under
the Loan Agreement are paid and the date on which such obligations
become due and payable, the Company is also required to pay
Hercules an end of term charge from $1.5 million to $3.7 million,
depending on the amount borrowed.
The Company may prepay the principal of any advance made pursuant
to the terms of the Term Loan Facility at any time subject to a
prepayment charge equal to: 2.50%, if such advance is prepaid in
any of the first 12 months following the Closing Date, 1.50%, if
such advance is prepaid after 12 months but prior to 24 months
following the Closing Date, and 1.0%, if such advance is prepaid
anytime thereafter.
If the Company fails to maintain an unrestricted cash balance of
$60 million, the Loan Agreement has a revenue financial covenant
that requires the Company to achieve certain trailing twelve-month
revenue targets tested quarterly.
All obligations under the Loan Agreement are unconditionally
guaranteed by the Company’s subsidiary Sense Photonics, Inc. The
Term Loan Facility is secured by substantially all of the Company’s
and the guarantors’ existing and after-acquired assets, including
all intellectual property, all securities in existing and future
domestic subsidiaries and 65.0% of the securities in foreign
subsidiaries, subject to certain exceptions and
exclusions.
The Loan Agreement contains customary covenants for transactions of
this type and other covenants agreed to by the parties, including,
among others, (i) the provision of annual, quarterly and monthly
financial statements, management rights and insurance policies and
(ii) restrictions on incurring debt, granting liens, making
acquisitions, making loans, paying dividends, dissolving, and
entering into leases and asset sales. The Loan Agreement also
provides for customary events of default, including, among others,
payment, bankruptcy, covenant, representation and warranty, change
of control, judgment and material adverse effect
defaults.
Material Cash Requirements
We are a party to many contractual obligations involving
commitments to make payments to third parties. These obligations
impact our short-term and long-term liquidity and capital resource
needs. Certain contractual obligations are reflected on the
condensed consolidated balance sheet as of March 31, 2022, while
others are considered future commitments. Our contractual
obligations primarily consist of non-cancelable purchase
commitments with various parties to purchase goods or services,
primarily inventory, entered into in the normal course of business
and operating leases. For information regarding our other
contractual obligations, refer to Note 7, Commitments and
Contingencies and our Annual Report on Form 10-K as filed with the
SEC on February 28, 2022.
Cash Flow Summary
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
|
(dollars in thousands) |
Net cash provided by (used in): |
|
|
|
Operating activities |
$ |
(21,827) |
|
|
$ |
(12,399) |
|
Investing activities |
(141) |
|
|
(597) |
|
Financing activities |
119 |
|
|
258,799 |
|
Operating Activities
During the three months ended March 31, 2022, operating activities
used $21.8 million in cash. The primary factors affecting our
operating cash flows during this period were our net loss of $32.4
million, impacted by our non-cash charges of $10.1 million
primarily consisting of stock-based compensation of $8.8 million, a
$1.7 million change in fair value of warrant liabilities,
depreciation and amortization of $2.4 million, change in
right-of-use asset of $0.6 million, inventory write down of $0.2
million and gain from disposal of property and equipment of $0.1
million. The changes in our operating assets and liabilities of
$0.4 million were primarily due to a decrease in prepaid expenses
and other assets of $2.5 million, a decrease in operating lease
liability of $0.8 million, an increase in inventories of $4.4
million, an increase in accounts payable and accrued and other
liabilities of $2.3 million, and a decrease in accounts receivable
of $0.8 million.
During the three months ended March 31, 2021, operating activities
used $12.4 million in cash. Non-cash charges of 11.3 million
primarily consisting of stock-based compensation of $5.3 million, a
$4.1 million change in fair value of warrant liabilities,
depreciation and amortization of $1.1 million, change in
right-of-use asset of $0.5 million, interest expense and
amortization of debt issuance costs and debt discount of $0.3
million. The changes in our operating assets and liabilities of
$2.8 million were primarily due to an increase in prepaid expenses
and other assets of $1.2 million, a decrease in operating lease
liability of $0.7 million, an increase in inventories of $0.5
million, a decrease in accounts payable and accrued and other
liabilities of $0.3 million, and an increase in accounts receivable
of $0.1 million.
Investing Activities
During the three months ended March 31, 2022, cash used in
investing activities was $0.1 million, which was related to
purchases of property and equipment, partially offset by sales of
property and equipment.
During the three months ended March 31, 2021, cash used in
investing activities was $0.6 million, which was related to
purchases of property and equipment.
Financing Activities
During the three months ended March 31, 2022, cash provided by
financing activities was $0.1 million, consisting primarily of
proceeds from exercise of stock options of $0.2 million, partially
offset by repurchase of shares of common stock and taxes paid
related to net share settlement of equity awards of $0.1
million.
During the three months ended March 31, 2021, cash provided by
financing activities was $258.8 million consisting primarily of
$291.5 million proceeds (net of $8.4 million of pre-Merger costs
relating to CLA) from the Merger and PIPE Investment offset by
offerings costs of $26.1 million, and proceeds from exercise of
stock options of $0.5 million, partially offset by repayment
of debt of $7.0 million. There were promissory notes to
related parties of $5.0 million that were issued and repaid during
the three months ended March 31, 2021.
Critical Accounting Policies and Estimates
Our critical accounting policies and estimates are described in
Management’s Discussion and Analysis of Financial Condition and
Results of Operations in our Annual Report on Form 10-K for the
year ended December 31, 2021. There have been no significant
changes to our critical accounting policies since the filing of our
Annual Report on Form 10-K for the year ended December 31,
2021.
Recent Accounting Pronouncements
Please refer to Note 2 in our unaudited condensed consolidated
financial statements contained elsewhere in this Quarterly Report
on Form 10-Q for recently adopted accounting pronouncements and
recently issued accounting pronouncements not yet adopted as of the
date of this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures about Market
Risk
We are exposed to market risks in the ordinary course of our
business. Market risk represents the risk of loss that may impact
our financial position due to adverse changes in financial market
prices and rates. Our market risk exposure is primarily the result
of fluctuations in interest rates and foreign currency exchange
rates.
We do not believe that inflation has had a material effect on our
business, results of operations or financial condition.
Nonetheless, if our costs were to become subject to significant
inflationary pressures, we may not be able to fully offset such
higher costs. Our inability or failure to do so could harm our
business, results of operations or financial
condition.
Interest Rate Risk
As of March 31, 2022, we had cash and cash equivalents of
approximately $160.8 million, out of which $153.0 million consisted
of institutional money market funds, which carries a degree of
interest rate risk. A hypothetical 10% change in interest rates
would not have a material impact on our financial condition or
results of operations due to the short-term nature of our
investment portfolio. In addition, subsequent to quarter end, we
received $20.0 million under the Loan Agreement. These borrowings
bear interest at variable rates which will carry interest rate risk
going forward.
Foreign Currency Exchange Risk
Our results of operations and cash flows are subject to
fluctuations due to changes in foreign currency exchange rates.
Substantially all of our revenue is generated in U.S. dollars. Our
expenses are generally denominated in the currencies of the
jurisdictions in which we conduct our operations, which are
primarily in the U.S. and to a lesser extent in Asia and Europe.
Our results of operations and cash flows are, therefore, subject to
fluctuations due to changes in foreign currency exchange rates and
may be adversely affected in the future due to changes in foreign
exchange rates. The effect of a hypothetical 10% change in foreign
currency exchange rates applicable to our business would not have a
material impact on our historical consolidated financial
statements. To date, we have not engaged in any hedging strategies.
As our international operations grow, we will continue to reassess
our approach to manage our risk relating to fluctuations in
currency rates.
Item 4. Controls and Procedures
Limitations on effectiveness of controls and
procedures
We maintain disclosure controls and procedures (as that term is
defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act)
that are designed to ensure that information required to be
disclosed in our reports under the Exchange Act is recorded,
processed, summarized and reported within the time periods
specified in the SEC’s rules and forms, and that such information
is accumulated and communicated to our management, including our
Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required
disclosures. In designing and evaluating our disclosure controls
and procedures, management recognizes that any controls and
procedures, no matter how well-designed and operated, can provide
only reasonable assurance of achieving the desired control
objectives. In addition, the design of disclosure controls and
procedures must reflect the fact that there are resource
constraints and that management is required to apply judgment in
evaluating the benefits of possible controls and procedures
relative to their costs.
Evaluation of disclosure controls and procedures
Our management, with the participation of our principal executive
officer and principal financial officer, evaluated, as of the end
of the period covered by this Quarterly Report on Form 10-Q, the
effectiveness of our disclosure controls and procedures (as that
term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act). Based on that evaluation, our principal executive officer and
principal financial officer concluded that our disclosure controls
and procedures were not effective as of March 31, 2022 due to the
material weaknesses in our internal control over financial
reporting described below.
Material Weaknesses and Remediation Plan
We identified material weaknesses in our internal control over
financial reporting. A material weakness is a deficiency, or a
combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a
material misstatement of our annual or interim financial statements
will not be prevented or detected on a timely basis.
We did not design and maintain an effective control environment
commensurate with our financial reporting requirements.
Specifically, we did not maintain a sufficient complement of
personnel with an appropriate degree of internal controls and
accounting knowledge, experience, and training commensurate with
our accounting and reporting requirements. This material weakness
contributed to the following additional material
weaknesses:
•We
did not design and maintain effective controls over the period-end
financial reporting process to achieve complete, accurate and
timely financial accounting, reporting and disclosures, including
segregation of duties and adequate controls related to journal
entries and certain other business processes, and verifying
transactions are properly classified in the financial statements.
This material weakness resulted in adjustments to several account
balances and disclosures in the consolidated financial statements
for the years ended December 31, 2019 and 2018, and adjustments to
the equity and warrant liabilities accounts and related disclosures
in the condensed consolidated financial statements for the three
months ended March 31, 2021.
•We
did not design and maintain effective controls over certain
information technology (“IT”) general controls for information
systems that are relevant to the preparation of our consolidated
financial statements. Specifically, we did not design and maintain
(i) program change management controls to ensure that information
technology program and data changes affecting financial IT
applications and underlying accounting records are identified,
tested, authorized and implemented appropriately and (ii) user
access controls to ensure appropriate segregation of duties and
that adequately restrict user and privileged access to our
financial applications, programs and data to appropriate personnel.
This material weakness did not result in a material misstatement to
the consolidated financial statements, however, the deficiencies,
when aggregated, could impact maintaining effective segregation of
duties, as well as the effectiveness of IT-dependent controls (such
as automated controls that address the risk of material
misstatement to one or more assertions, along with the IT controls
and underlying data that support the effectiveness of
system-generated data and reports) that could result in
misstatements potentially impacting all financial statement
accounts and disclosures that would not be prevented or
detected.
Additionally, each of these material weaknesses could result in a
misstatement of account balances or disclosures that would result
in a material misstatement to the annual or interim consolidated
financial statements that would not be prevented or
detected.
We have taken several measures to remediate the foregoing material
weaknesses. To date, our efforts have included the
following:
•Recruiting
additional personnel with appropriate internal controls and
accounting knowledge and experience commensurate with our
accounting and reporting requirements, in addition to engaging and
utilizing third party consultants and specialists.
•Enhancing
entity level controls (ELCs) including increasing Board and Audit
Committee oversight, expanding senior management review of
financial and business performance, creating an internal audit
function and charter, and providing code of conduct
trainings.
•Strengthening
IT governance and designing IT general controls including
restricted user access to our internal systems for financial
reporting, change management, program development and computer
operations.
•Designing
additional controls for financial close and reporting including
review of accounting policies, journal entry review controls,
review of significant or non-routine transactions, period end close
procedures, financial statement preparation, review, and
reporting.
While these actions and planned actions are subject to ongoing
management evaluation and will require validation and testing of
the design and operating effectiveness of internal controls over a
sustained period, we are committed to continuous improvement and
will continue to diligently review our internal control over
financial reporting.
Changes in Internal Control over Financial Reporting
Other than execution of the material weakness remediation plan
activities described above, there has been no change in our
internal control over financial reporting (as that term is defined
in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the
three months ended March 31, 2022 that has materially affected, or
is reasonably likely to materially affect, our internal control
over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
On June 10, 2021, we received a letter from the SEC notifying us of
an investigation and document subpoena. The subpoena seeks
documents regarding projected financial information in CLA’s Form
S-4 registration statement filed on December 22, 2020. We have
complied with the SEC’s requests to date; however, the SEC may
request additional documents or information. Should the SEC pursue
this matter further, it could have a material impact on our
business and operations.
From time to time, we have been and may again become involved in
legal proceedings arising in the ordinary course of our business.
There is no material litigation, arbitration or governmental
proceeding currently pending or to Ouster’s knowledge, threatened
against us or any members of Ouster’s management team in their
capacity as such. See Part I, Item 1 “Financial Statements
(Unaudited) — Note 7. Commitments and Contingencies”
Item 1A. Risk Factors
There have been no material changes from the risk factors disclosed
in the Company’s Annual Report on Form 10-K filed with the SEC on
February 28, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds
Unregistered Sales of Equity Securities
We did not sell any securities during the three months ended March
31, 2022 that were not registered under the Securities
Act.
Issuer Purchases of Equity Securities
We did not purchase any of our equity securities that are
registered under Section 12(b) of the Exchange Act during the three
months ended March 31, 2022.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Number |
|
Description |
|
Incorporated by Reference |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Form |
|
File No. |
|
Exhibit |
|
Filing Date |
|
Filed/ Furnished herewith |
|
|
|
|
S-4/A |
|
333-251611 |
|
2.1 |
|
2/10/2021 |
|
|
|
|
|
|
S-4 POS |
|
333-251611 |
|
3.1 |
|
3/10/2021 |
|
|
|
|
|
|
S-4 POS |
|
333-251611 |
|
3.2 |
|
3/10/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
** |
|
|
|
|
|
|
|
|
|
|
|
|
** |
101.INS |
|
Inline XBRL Instance Document - the instance document does not
appear in the Interactive Data file because its XBRL tags are
embedded within the Inline XBRL document.
|
|
|
|
|
|
|
|
|
|
* |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
|
|
|
|
|
|
* |
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase
Document |
|
|
|
|
|
|
|
|
|
* |
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase
Document |
|
|
|
|
|
|
|
|
|
* |
101.LAB |
|
Inline XBRL Taxonomy Label Linkbase Document |
|
|
|
|
|
|
|
|
|
* |
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase
Document |
|
|
|
|
|
|
|
|
|
* |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and
contained in Exhibit 101) |
|
|
|
|
|
|
|
|
|
|
____________
|
|
|
|
|
|
† |
The annexes, schedules, and certain exhibits to this Exhibit have
been omitted pursuant to Item 601(b)(2) of Regulation S-K. The
Registrant hereby agrees to furnish supplementally a copy of any
omitted annex, schedule or exhibit to the SEC upon
request. |
^ |
Certain portions of this exhibit have been omitted pursuant to Item
601(a)(5) of Regulation S-K or redacted pursuant to Item
601(b)(10)(iv) of Regulation S-K.
|
* |
Filed herewith. |
** |
Furnished herewith. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
Ouster, Inc. |
Date: May 6, 2022 |
By: |
/s/ Anna Brunelle |
|
Name: |
Anna Brunelle |
|
Title: |
Chief Financial Officer (principal
financial officer and principal accounting
officer)
|
Ouster (NYSE:OUST)
Historical Stock Chart
From May 2022 to Jun 2022
Ouster (NYSE:OUST)
Historical Stock Chart
From Jun 2021 to Jun 2022